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ABSTRACT  
The hyperacute immune response observed in humans after xenotransplantation is 
mainly induced by the α(1,3)Galactosyl (αGal) epitopes expressed on xenografts and the 
pre-existing anti-αGal antibodies that recognize these epitopes. Based on this hyperacute 
rejection, we hypothesized that human cancer cells genetically modified to express the 
αGal epitope could provide a new anti-cancer vaccine. This hypothesis was previously 
studied using the α1,3-galactosyltransferase knockout (αGT KO) mouse model and B16 
melanoma cells genetically modified to express αGal epitopes (B16αGal). In this model, 
the B16αGal vaccine showed efficacy in treating pre-existing subcutaneous and 
pulmonary αGal-negative B16 melanomas in mice. Furthermore, adoptively transferred 
lymphocytes from mice vaccinated with the B16αGal vaccine elicited a therapeutic 
response in mice bearing pulmonary tumors. In an attempt to increase the efficacy of the 
B16αGal vaccine, in the present study, IL-15-expressing vaccine cells (B16IL-15) were 
administered to mice in combination with the B16αGal vaccine with or without B16N/V 
vaccine cells (irradiated B16F0 melanoma cells). As documented in literature, IL-15 
stimulates the proliferation and maintenance of memory CD8+ T cells. We exploited 
these effects of IL-15 in preventive and therapeutic experiments, wherein B16 tumors 
were implanted either subcutaneously or intravenously in αGT KO mice. In all the 
efficacy studies, the combination therapy showed efficacy in vaccinated mice versus 
control mice receiving no vaccination. In three out of five in vivo experiments, mice 
receiving the combination therapy were more effectively treated for B16 melanomas 
compared to mice receiving B16αGal vaccine (with or without B16N/V vaccine). 
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Moreover, long-term memory CD8+ T cells adoptively transferred from mice receiving 
the combination therapy successfully treated mice with pulmonary B16 melanomas. In 
vivo 5,6-carboxyfluorescein diacetate, succinimidyl ester (CFSE) labeling experiments 
demonstrated that mice receiving the combination therapy developed CD8+ T cells which 
proliferated to a greater degree than CD8+ T cells from mice vaccinated with B16αGal 
plus B16N/V vaccine. In conclusion, the results obtained in this study using the described 
murine system demonstrate a trend supporting the hypothesis that a combined therapy of 
B16αGal plus B16IL-15 vaccines provides a potential improved treatment outcome 
compared to the B16αGal vaccine alone.  
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INTRODUCTION 
Cancer and Immunotherapy 
Cancer is a major health problem in developed countries including the United 
States where one in four deaths reported is due to cancer (1). Surgery, radiotherapy, and 
chemotherapy are the primary approved modes of treatment for cancer patients. 
However, the complications that accompany these therapies and the cases and forms of 
cancer refractory to these treatment modalities have prompted a search for more effective 
treatments with less harmful side effects (2). A promising therapy that has been 
extensively studied for the past two decades is active immunotherapy. Various cancer 
vaccines have already shown some degree of clinical benefit (3). The first cancer 
vaccines were composed of irradiated or inactivated whole tumor cells that were reported 
to express mutant antigens that rendered them more immunogenic (2). One potential 
advantage that active immunotherapy has over other therapies is specificity (2). Vaccines 
can target antigens that are only expressed by tumor cells, thereby rendering normal 
tissue unharmed. Our current efforts are focused on using whole tumor cells in order to 
provide a broader source of antigens. This may be advantageous since information is 
often lacking concerning the most relevant tumor antigens in most human cancers (3). 
Cancer vaccines can be designed to elicit both humoral and cellular immune responses. 
The source of cells for cancer vaccines can be either autologous or allogeneic tumor cells 
(4). Autologous vaccines have the advantage of containing patient specific and 
potentially rare antigens that are appropriately HLA-matched for optimum antigen 
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presentation to T cells. There are, however, two major disadvantages to autologous 
vaccines in treating human cancer: first, the impracticality of manufacturing this type of 
vaccine in a timely manner and in adequate quantities; and second, the great difficultly of 
cell characterization since the vaccines are customized for each patient. These important 
issues have skewed efforts at many institutions toward the production of well-
characterized allogeneic tumor vaccines. Allogeneic vaccines could be made available in 
sufficiently large quantities to treat different patients and at all stages of the disease (4, 
5).  
Whole Cell Cancer Vaccines  
Different approaches using cell-based vaccines are currently being explored in 
clinical trials. Some appear promising while others have been discontinued. For example, 
Canvaxin, developed by Dr Donald Morton in 1984 and used at the John Wayne Cancer 
Institute (JWCI) was an allogeneic whole-cell vaccine that consists of three melanoma 
cell lines selected from among more than 150 melanoma cell lines. This vaccine was 
designed to include more than 20 immunogenic melanoma-associated as well as non-
melanoma tumor-associated antigens from these three cell lines. Canvaxin was 
intradermally injected as irradiated whole cells adjuvanted with Bacillus Calmette-Guerin 
(BCG), a strain of Mycobacterium bovis (6). The purpose of introducing an immune 
adjuvant is to further enhance the vaccine’s immune response by recruiting antigen-
presenting cells (APCs), macrophages, and B cells to the site of vaccination. In theory, 
MHC class II presentation by APCs and B cells were supposed to activate CD4+ T cells 
which should further activate B cells and macrophages (7). Activated B cells were to 
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produce antibodies against tumor-specific antigens which might trigger complement 
destruction of tumor cells and antibody-dependent cellular cytotoxicity. Furthermore, 
through their Fcγ receptors, APCs in turn would uptake tumor-specific antigens and 
present them to CD8+ T cells, thus in theory eliciting a cytotoxic response. Patients 
vaccinated with Canvaxin showed humoral as well as cell-mediated responses against 
autologous melanoma-associated antigens (8). In 1998, phase III trials were initiated for 
the Canvaxin vaccine. Patients with stage III or IV melanoma were treated with Canvaxin 
vaccine with or without BCG after complete resection of metastatic melanoma. 
Unfortunately, in 2005, these trials were halted because of a lack of vaccine efficacy; 
vaccine treatment was no better than placebo treatment (4).  
Another allogeneic whole-cell vaccine is GVAX which is composed of two 
irradiated prostate cancer cell lines, LN-CaP and PC-3, both genetically modified to 
produce granulocyte macrophage colony-stimulating factor (GM-CSF) (9). This cytokine 
acts as a chemo-attractant of granulocytes and differentiation factor that contributes to the 
maturation and activation of cells belonging to the myeloid lineage such as monocytes, 
neutrophils, macrophages, dendritic cells, and eosinophils (7). It participates in producing 
“danger signals” needed to activate the immune system, break tolerance, and stimulate an 
anti-tumor response (9-12). Importantly, when compared to multiple cytokines and 
growth factors transduced into B16 melanoma cell vaccines, GM-CSF was shown to be 
the most potent at eliciting an anti-tumor response (13, 14). Ten different B16 melanoma 
tumor cell vaccines were generated, each expressing a different cytokine or growth 
factor, and used to prevent a challenge with B16 melanomas in mice (13). Only irradiated 
B16 melanoma tumor cells genetically engineered to express GM-CSF conferred 100% 
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protection in mice. In addition, when the 10 cytokines were compared in the poorly 
immunogenic mouse tumor model, GM-CSF was classified as the most potent cytokine 
in terms of generating CD4+ and CD8+ T-cell responses. Additionally, vaccinated mice 
were not only able to survive both immediate and late challenge with B16 melanoma, but 
were also able to reject pre-established tumors. In multiple murine models, vaccination 
with irradiated cells expressing GM-CSF resulted in enhanced tumor antigen presentation 
by DCs and macrophages, enhanced CD4+, CD8+, and CD1d-restricted NK T cell 
responses, and enhanced antibody mediated protective immunity (15). Phase III clinical 
trials are currently under study for the GVAX vaccine. 
For an optimal T cell activation to occur, T cells need to interact with a specific 
antigen (16) and engage with costimulatory ligands on APCs. Failure to bind to 
costimulatory ligands can render T cells anergic (17). The cytotoxic T lymphocyte 
antigen (CTLA-4) is a receptor on T cells that blocks the costimulatory signal by binding 
to B7 molecules on APCs. The administration of anti-CTLA-4 antibodies has enhanced 
anti-tumor responses in several animal tumor models (18, 19) and this antibody has been 
used in combination with prostate cancer vaccines (9). Recently, the National Cancer 
Institute has developed a vector-based vaccine that uses the same rationale of anti-CTLA-
4 antibody (20). This vaccine is composed of vaccinia and fowlpox viruses expressing 
prostate-specific antigen (PSA) and three human costimulatory molecules, designated 
TRICOM (TRIad of COstimulatory Molecules: B7.1, intercellular adhesion molecule-1 
(ICAM-1), and lymphocyte function-associated antigen-3 (LFA-3) (21)). The vaccine has 
shown clinical responses based on Response Evaluation Criteria in Solid Tumors 
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(RECIST) and drops in serum PSA in phase I/II trials in patients with advanced prostate 
cancer  (3, 20).    
Another immunotherapy cell-based vaccine is Sipuleucel-T (Provenge) which is 
composed of autologous dendritic cells (DCs) cultured with a fusion protein, PA2024, 
which consists of prostatic acid phosphatase (PAP), an antigen expressed in most prostate 
cancers but not by normal tissue, and GM-CSF (22-24). Ex vivo incubation with PA2024 
will activate dendritic cells and upregulate their costimulatory molecules. These cells are 
then injected back into patients where they will hopefully home to the lymph nodes and 
activate CD4+ and CD8+ T cells generating an effective antigen specific cellular immune 
response. Arguably, DCs are the most potent APCs and can solely initiate a T-cell 
immune response of naive T cells (25). Sipuleucel-T is now under study in a phase III 
clinical trial in hormone refractory prostate cancer (HRPC) patients. 
The αGalactosyl Epitope   
Based upon the hyperacute rejection found to occur with xenotransplants in 
primates, our laboratory developed a whole-cell Galα1,3Gal epitope (αGal)-expressing 
vaccine (HyperAcute vaccine). The αGal epitope is the main antigen trigger of the 
hyperacute rejection in humans after xenotransplantation (26). All mammals except 
humans, apes, and Old World monkeys, express αGal epitopes on their cells and tissues 
(27). The enzyme responsible for the synthesis of the αGal epitope is α1,3-
galactosyltransferase (αGT). In the Golgi apparatus, αGT adds a terminal galactose onto 
glycoproteins and glycolipids in a specific α1-3 glycosidic linkage (28). This enzyme is 
not transcribed in humans due to a mutation in the upstream regulatory sequence of the 
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αGT gene (26). In humans, the αGal moiety expressed by the normal bacterial flora found 
in intestines and lungs stimulate the production of anti-αGal antibodies found in blood. 
These naturally acquired anti-αGal antibodies constitute 1% of circulating antibodies in 
humans (29). After xenotransplantation, anti-αGal antibodies bind to αGal epitopes on 
xenografts. This will then initiate complement lysis and activation through the classical 
pathway and natural killer (NK)-mediated antibody dependent cell cytotoxicity (ADCC) 
(26, 30). This is an acute response and leads to xenotransplant rejection and destruction 
within minutes to hours after transplantation.  
Development of The αGal-expressing Cancer Vaccine 
Exploitation of this aspect of the hyperacute rejection of xenotransplants as a 
cancer therapy resulted from early studies conducted by Dr. Charles Link at the Stoddard 
Cancer Research Center (SCRI) in Des Moines, Iowa. In these studies, vector producer 
cells (VPCs) were injected into the peritoneal cavity of ovarian cancer patients. 
Following injection, the VPCs were destroyed by the peritoneal fluid.  Other studies 
reported anti-tumor activity in the context of several human gene therapy cancer trials 
using murine retroviral VPCs (31). Those trials were based on the hypothesis that murine 
retroviral VPCs would efficiently transfer a suicide gene to the patient’s solid tumor cells 
in vivo, thus, precipitating the subsequent destruction of tumor cells. Our team speculated 
that the anti-tumor responses observed in those trials were more dependent on an immune 
response to the αGal epitope expressed by the murine VPCs than on the gene transfer. 
This bystander effect might have made it possible for an entire tumor to be destroyed 
even though only a small portion of the tumor was affected by gene transfer. In the 
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ovarian cancer trial conducted at SCRI, four of ten patients demonstrated evidence of 
anti-tumor response, including one complete remission by CT scan. Patients showed 
tumor regression despite minimal transgene transfer suggesting that gene transfer was not 
likely to be responsible for the anti-tumor activity. An increase in anti-αGal antibody titer 
was shown in the peritoneal cavity after VPC infusion without an increase in total IgG 
and IgM immunoglobulin levels, suggesting that the increased anti-αGal antibody titer 
was the result of a specific immune response against αGal epitopes expressed by the 
murine VPCs. These findings correlated with the timing of the anti-tumor response 
observed. The patient who manifested the best and most durable anti-tumor response had 
a large increase in her serum titer of anti-αGal antibodies (32-fold increase) and a rapid 
increase in the ability of her peritoneal fluid to kill murine VPCs as measured ex vivo. 
These data supported a correlation between anti-αGal immunity and tumor response (32-
37). 
Data from this clinical trial inspired our team to propose a model to test the 
hypothesis of whether or not human cancer cells expressing the αGal epitope would 
induce an anti-tumor immunity and thus qualify as an anticancer vaccine candidate (38, 
39). This hypothesis was tested in αGT knockout (KO) mice (40) which, similar to 
humans, do not express αGal epitopes on their cells and thus provide an ideal model to 
study the in vivo immune response of αGal epitopes. These mice upon injection with 
rabbit red blood cells (RRBCs) (38, 41) or oral immunization with bacteria (42) produced 
high anti-αGal antibody titers, similar to those observed in humans. The B16BL6 
melanoma cell line is devoid of the αGal epitope and was transduced with a retroviral 
vector expressing the α(1,3)GT and neomycin-resistance (NeoR) genes (B16αGal), or a 
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retroviral vector expressing the neomycin-resistance gene alone (B16NeoR). It was 
shown using a functional assay that the presence of anti-αGal antibodies and complement 
is necessary to elicit cell lysis of αGal-expressing cells (39). Forty-five percent of mice 
with pre-existing anti-αGal antibodies rejected a subcutaneous challenge with αGal-
positive melanoma cells, remaining tumor-free for more than 80 days. In contrast, 90% of 
mice injected with αGal-negative B16 melanoma cells (B16Null) had developed 
melanoma. Similar results were obtained when this experiment was repeated (39). Mice 
surviving the lethal challenge of B16αGal were further protected from a subcutaneous re-
challenge with B16Null. All control mice died from tumor progression while all mice 
injected with B16αGal survived the tumor and remained tumor-free for more than 70 
days. This long-lasting anti-tumor immunity was induced by cytotoxic T cells specific for 
B16 melanoma cells (39).      
Further modeling of metastatic melanoma using the αGT KO murine model was 
performed. The αGT KO mice were challenged with tumor, either subcutaneously to 
model solid melanomas, or intravenously to model disseminated melanomas, and then 
vaccinated with irradiated whole cells either expressing or not expressing the αGal 
epitope (43). In the pre-established subcutaneous model, mice vaccinated with B16αGal 
showed significant reduction in tumor size 30 days past tumor challenge compared to 
control mice. Similarly, in the pre-established pulmonary metastatic model, 30 days after 
the intravenous administration of tumor cells, metastases burden of mice vaccinated with 
B16αGal was significantly lower compared to mice vaccinated with B16NeoR or non-
vaccinated mice. Importantly, all mice vaccinated with B16αGal remained tumor-free. 
Moreover, when T-cell mediated immunity (CD8+ T cells) was adoptively transferred 
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from mice vaccinated with B16αGal to syngeneic mice bearing B16 melanoma, this led 
to a therapeutic response in 11 out of 12 mice, whereas mice of the control groups had 
significantly higher numbers of lung metastases. The B16 melanoma specificity of T cells 
harvested from αGal-vaccinated mice was also shown in vitro. Based in part on these 
data, several phase I/II clinical trials using human allogeneic cancer vaccines expressing 
αGal epitopes are currently open to treat patients with lung, prostate, pancreatic, and 
melanoma cancer.  
Combination Therapy Using Cancer Vaccines 
Despite the advances made in active immunotherapy, no therapeutic vaccine has 
yet been approved by the Food and Drug Administration. Current approaches in cancer 
therapy involve vaccination in combination with other therapies and these strategies are 
showing promises both in preclinical and clinical studies. 
As reviewed recently by Schlom et al., there are primarily four different strategies 
of combination therapy using cancer vaccines under investigation in which some clinical 
efficacy has been shown (3). These are: 
1. Conventional combination therapy in which vaccines are used with 
chemotherapeutic agents, such as 5-fluorouracil and docetaxel (44, 45).  
2. Multiple vaccine therapies in which different types of vaccines are used 
together. For example, in an attempt to treat patients with prostate cancer, 
Kaufman is using vaccinia virus in combination with fowlpox virus (46). 
3. Phenotype alterations in tumor cells in which therapeutics are used to 
alter the phenotype of cancer cells to make them more susceptible to T-
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cell-mediated cytotoxicity. These treatments include radiation as well as 
chemotherapeutic agents (47). 
4. Vaccine in combination with agents that affect the host immune 
response in which stimulants or inhibitors of immune regulatory cells or 
molecules are used. Stimulants include cytokines, such as granulocyte 
macrophage colony-stimulating factor (GM-CSF) which has been used in 
clinical trials (48). Also, IL-15 and IL-7 have been described as useful 
adjuvants as they have the ability to enhance memory-T cell responses (3) 
(49). BCG vaccine and CpG motifs have also been used as immune 
stimulants in combination with vaccines (50, 51). Inhibition has been 
targeted against T regulatory cells (52-54), whereas other potential targets 
are immunosuppressive molecules, such as transforming growth factor-β 
and IL-10 (3). 
IL-15  
Since the current trend in cancer vaccine field is to implement combinatory 
therapy trials, we proposed to explore if IL-15 and B16αGal vaccine combined therapy 
would increase the efficacy of our vaccine.  
IL-15 is a 14-15kDa cytokine protein that signals through the β and γ chains of 
the IL-2 receptor in addition to the unique α chain, IL-15Rα. IL-15 binds to IL-15Rα with 
high affinity and binds to IL-2/15R β and the common γ chain (γc) heterodimer with an 
intermediate affinity (55, 56). IL-15 is synthesized by dendritic cells, monocytes, and 
fibroblasts (49, 57, 58), and IL-15Rα is expressed by hematopoietic and parenchymal 
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cells (59). The intracellular trafficking of IL-15 and IL-15Rα is unique among 
interleukins in that unlike other ligand/receptor complexes, they are recycled between the 
plasma membrane and endosomes for many days and are not targeted for degradation in 
lysosomes. This provides a reservoir of membrane-bound and biologically active IL-15 
(60). Only IL-15Rα is involved in IL-15/IL-15Rα  recycling (61). Through IL-15Rα on 
dendritic cells and monocytes, IL-15 is trans-presented to NK cells and CD8+ T cells. 
Only the expression of the IL-2/15Rβ and γc dimer is required on target cells for 
signaling (62). This trans-presentation is critical for the activation of NK cells, the 
differentiation of CD8+ T cells to memory cells and the maintenance of CD8+ memory T 
cells (49, 62, 63).  
IL-15 has been studied extensively as a possible adjuvant for cancer vaccines and 
as a substitute for IL-2. IL-15 and IL-2 share many functions. They stimulate the 
proliferation of activated CD4-CD8-, CD4+CD8+, CD4+, and CD8+ T cells, facilitate the 
induction of CTLs, induce the proliferation of and immunoglobulin synthesis by B cells, 
and stimulate the generation, proliferation, and activation of NK cells (49). However, IL-
15 potentially supersedes IL-2 as an adjuvant for cancer vaccines, in that it is not 
involved in the elimination of self-reactive T cells. Also, the use of high doses of IL-2 has 
shown substantial toxicity in clinical trials (64, 65). In addition, IL-2 is required to 
maintain the competitive fitness of regulatory T (Treg) cells and for their retention in the 
peripheral T cell population, while no marked effects have been reported by IL-15 on 
Treg cells in murine models (49).  However, γc signals are required for the development 
of Treg cells and are able to compensate for the absence of IL-2 (66-69). Ideally, it is 
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important to control or reduce Treg cells because they reduce the induction of immune 
responses and thus impair the anti-tumor immune responses (66).  
IL-15 in Cancer Therapy 
The contribution of IL-15 to cancer immunosurveillance has been tested using 
different methods. IL-15 has been used as an exogenous protein (70-72), expressed by a 
vector (55, 73), and expressed by whole cells (74, 75). Also, transgenic mice 
constitutively expressing IL-15 (or IL-15Rα) or not expressing IL-15 (or IL-15Rα) have 
been produced to study the effects of IL-15 on cancer (60, 61).  
In an adenocarcinoma study conducted by Meazza et al. (75), more than 50% of 
BALB/c mice subcutaneously injected with cells of the TS/A adenocarcinoma cell line 
expressing the IL-15 gene (TS/A IL-15) were tumor-free for at least 8 weeks, while 95% 
and 100% of mice injected with control cells developed tumor within 21 days of tumor 
challenge. Similarly, TS/A IL-15 cells were significantly less metastatic than control cells 
after 21 days of intravenous administration of the cells.  In this study, in vitro cultures of 
splenocytes harvested from TS/A IL-15-vaccinated mice and stimulated with irradiated 
TS/A cells contained significantly higher concentrations of IFN-γ than cultures with 
splenocytes of control mice. CD8+ T cells were the major producers of this cytokine as 
indicated by a CD8+ T cells depletion experiment in vitro. Furthermore, mitomycin or γ-
irradiated TS/A IL-15 cells showed protection in 60% of mice when administered 
intraperitoneally to treat pre-established wild-type pulmonary adenocarcinoma tumor, 
while all control mice developed lung metastases after 21 days of metastasis implantation 
(75).   
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IL-15 transgenic mice (IL-15 Tg), constitutively overexpressing IL-15, showed 
significant protection from a subcutaneous challenge with B16F10 melanoma cells when 
compared with non-transgenic congenic mice (non-Tg) (76). More importantly, when 
these Tg mice were depleted of CD8+ T cells using anti-CD8 monoclonal antibodies, 
B16F10 tumor growth progressed significantly when compared with mice receiving 
control IgG. Also, NK cells contributed to this protection as evidenced by in vivo NK cell 
depletion experiments. In another study, similar protection from MC38 colon carcinoma 
has been demonstrated in IL-15 transgenic mice, constitutively overexpressing IL-15. In 
this model, wild-type congenic mice died from pulmonary metastases within 6 weeks of 
tumor challenge, whereas transgenic mice survived the challenge with no metastases for 
more than 8 months (60). Thus, at least in mice, IL-15 can result in protection from tumor 
challenges.  
Effects of IL-15 on CD8+ T Cells 
It is well established now that IL-15 enhances the maintenance and proliferation 
of memory CD8+ T cells (49, 63, 77-81). In a study conducted by Oh et al. (82), female 
BALB/c mice were immunized with a vaccinia virus (VV) expressing the HIV-1 gp160 
alone (vPE16), vPE16 and VV expressing human IL-2 (VV-IL-2), or vPE16 and VV 
expressing human IL-15 (VV-IL-15). Co-immunization with VV-IL-15 maintained 
relatively higher and steady levels of CD8+ T cells in vivo, measured by in vitro tetramer 
binding assays, for at least 14 months when compared to the other groups. These data 
were consistent with the levels of antigen-specific CD8+ T cell production of IFN-γ. In an 
attempt to study the effects of IL-15 on CD8+ T cells proliferation in vivo, vaccinated 
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mice were sacrificed 3 months after the last vaccination and CD8+ T cells were 
adoptively transferred to naïve mice. After two months, antigen-specific CD8+ T cells 
harvested from mice co-vaccinated with VV-IL-15 showed the greatest proliferation 
compared to CD8+ T cells harvested from other groups of mice (82). In a recent in vitro 
study, human T cells transduced with a retroviral vector expressing IL-15 became 
immortalized and had phenotypically evolved into a pure CD8+ T cells population (83). 
Furthermore, the anti-tumor immunity of CD8+ T cells was compromised in 
B16F10 melanoma-bearing IL-15KO mice, indicating the importance of endogenous 
production of IL-15 in maintaining the cytotoxic function of CD8+ T cells (71). Of note, 
it has been reported that IL-15 KO mice show marked reduction in CD8+CD44hi memory 
T cells (49, 56). Interestingly, IL-15 enhances the proliferation of memory CD8+ T cells 
regardless of antigen administration (77, 82, 84-86).  
One of the mechanisms proposed for the IL-15 mediated anti-tumor response is its 
inhibition of IL-2-mediated activation-induced cell death which involves the elimination 
of self-reactive T cells (79). IL-15/IL-15Rα binding is also critical for early activation of 
antigen-presenting cells (87). In addition, IL-15 plays a pivotal role in the proliferation 
and differentiation of NK cells, another important set of cytotoxic cells that have anti-
cancer activity (88).  
The Anti-tumor Activity of CD8+ T Cells 
The power of CD8+ T cells to destroy tumors has been extensively demonstrated. 
Indeed many experiments have been done in which CD8+ T cells were able to eradicate 
large masses of tumor in vivo in murine models (75, 76). In vivo depletion of CD8+ T 
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cells using anti-mouse CD8 monoclonal antibodies resulted in recurrent adenocarcinoma 
in all syngeneic mice after a subcutaneous challenge with TS/A IL-15 cells. These effects 
were statistically significant, compared to mice not depleted of CD8+ T cells (75). In 
another example using B16F10 tumor in IL-15 transgenic mice, subcutaneously 
administered tumors were significantly larger in mice depleted of CD8+ T cells than in 
mice intraperitoneally injected with control IgG (76). Considerable attention has been 
given to these cells because they recognize and kill MHC class I-positive cells, a 
characteristic of most tumor cells (89). Indeed adoptive transfer to cancer patients of 
melanoma-specific CD8+ T cells has been done with rare occurrences of serious toxicity 
(90, 91).  
B16αGal and B16IL-15 Combination Therapy for Melanoma 
The prolonged survival of cytotoxic memory CD8+ T cells is desired to provide a 
durable protection in cancer patients receiving immunotherapy. Thus, we hypothesized 
that vaccination with IL-15-expressing vaccines will increase the efficacy of αGal-
expressing cancer vaccines by inducing the maintenance and proliferation of memory 
cytotoxic CD8+ T cells. We tested this hypothesis in the αGT KO mouse model described 
above. The B16F0 melanoma cell line was transfected with a plasmid expressing human 
IL-15. Human IL-15 has previously shown activity in murine models (55, 70, 82, 92). 
Production of IL-15 was measured by ELISA and six clones expressing IL-15 were 
chosen for the purpose of this study. Those B16IL-15 clones were pooled, irradiated, 
tested for IL-15 production, and used to protect mice from a challenge with B16 
melanoma in combination with B16αGal vaccine. Also, the combination therapy was 
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examined in therapeutic experiments where mice were first challenged with B16 
melanoma tumor cells and then vaccinated. Tumor was implanted either subcutaneously 
or to detect any effects of the combination therapy on tumor metastases, mice had also 
received intravenous doses of tumor cells. The effects of vaccination in the presence of 
IL-15 on the cytotoxic activity of CD8+ T cells was studied in vivo by adoptive transfer 
experiments to mice bearing B16 melanoma. During this study, some techniques needed 
to be optimized while other techniques needed to be initiated. The CFSE labeling of 
CD8+ T cells was one of the techniques accomplished in this study and was used to detect 
any effects of the in vivo and in vitro administration of IL-15 on the proliferative 
potential of CD8+ T cells.   
Results in this study illustrated a trend indicating that administration of the 
combination therapy consisting of B16αGal plus B16IL-15 vaccination might have the 
potential of providing a better therapeutic approach than administering the B16αGal 
vaccine alone.  
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MATERIALS AND METHODS 
Plasmid  
The plasmid hpIL-15/pEF-Neo was generously provided by Yutaka Tagaya (93). 
It is a 5400-bp plasmid and expresses human IL-15 under the control of the elongation 
factor 1 α (EF1α) promoter.  
Propagation of the plasmid was done using heat shock transformation of 
chemically competent E.coli DH5α bacteria and subsequent culture, all following 
standard protocols. QIAGEN Plasmid Maxi Kit was used for plasmid DNA purification, 
and plasmid identity was confirmed by restriction digestion analysis. 
Production of B16IL-15 Cell Line 
Unless otherwise stated, all culture conditions involved incubation of cells at 
37OC, in 5% CO2, and in complete medium consisting of Dulbecco’s Modified Eagle 
medium (DMEM) supplemented with 5% fetal bovine serum (FBS), L-glutamine, 
glucose, and sodium pyruvate.  The B16F0 cell line is a spontaneous melanoma cell line 
derived from C57BL/6J mice, with a haplotype of H-2b/b (94). Cells of B16F0 cell line do 
not express the αGal epitope. Cultures of the B16F0 melanoma cell line were transfected 
with hpIL-15/pEF-Neo using the Lipofectamine TM 2000 reagent (Invitrogen, Carlsbad, 
CA, used at a ration of 1µg DNA: 2.5µL Lipofectamine TM 2000). The B16F0 cells were 
seeded into Petri dishes, at a density of 90% confluence in a volume of 5ml media 
without antibiotics. Twenty four hours post plating cells were transfected with 24µg 
DNA per plate. Following lipofection, stable transfectants were selected for by culturing 
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cells in a medium supplemented with Genetecin at a final concentration of 1mg/mL.  
Selection continued for 1 month, and medium was changed every 5 days.  Clonal 
selection was conducted by limiting dilution and resultant clones were tested for IL-15 
production by ELISA using a Human IL-15 kit (Human IL-15 Set; BD OptEATM, San 
Diego, CA). Concurrently cell proliferation was measured using the WST-1 reagent 
(Roche, Basel, Switzerland).  Briefly 10µL of WST-1 was added to 100µL fresh medium, 
which was applied to cells after media had been collected to measure IL-15.  The 
absorbance of the WST-1 medium was read at 440nm every 30 mins during incubation. 
B16 Melanoma Cell Vaccines  
Cultures of the B16F0 melanoma cell line were transduced with pHSPA, an HIV–
based vector encoding the α1,3-galactosyltransferase (αGT) gene under the control of the 
PGK promoter (LTR-PGK-αGT-sinLTR). The expression, or lack thereof, of αGal 
epitopes on αGal-expressing melanoma cells (hereafter B16αGal) and non-transduced 
B16F0 control cells (hereafter B16N/V) was tested using an αGal binding lectin (FITC-
labeled Griffonia simplicifolia isolectin B4 (IB4)) and detected by florescent-activated 
cell sorting, FACS. The B16F0, B16αGal, and B16IL-15 cells were γ-irradiated (200 Gy) 
and all vaccine lots produced were tested for Mycoplasma (MycoSensorTM PCR assay, 
Stratagene, La Jolla, CA) and viability using Propidium Iodide (PI) staining. All B16N/V 
and B16αGal cell vaccine lots were tested for αGal expression and B16IL-15 cell vaccine 
lots for IL-15 production by ELISA. 
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The αGT KO Mouse Model  
Several mice of the original colony αGT KO mice were purchased from Dr. J.B. 
Lowe (University of Michigan) and acted as founders of the colony at New Link Genetics 
(40). These early generation αGT KO mice expressed both H-2 b and d haplotypes, as 
these mice were generated from crosses involving C57BL/6, DBA/2J, and 129sv inbred 
mouse strains.  Subsequently αGT KO mouse colonies homozygous for either haplotype 
H-2b/b or H-2d/d were generated at the Iowa State University Laboratory Animal Resource 
facility by our laboratory members. Animals used in this study were αGT KO mice that 
are homozygous for H-2b/b haplotype (Figure 5). FITC-labeled IB4 was diluted 1:10 in 
serum-free medium (Lonza, Allendale, NJ) and added to peripheral blood lymphocytes 
isolated from mice. Cells were stained for 45 mins at 4°C in the dark, washed and 
analyzed by FACS. For haplotype determination, peripheral blood lymphocytes were 
stained with the following monoclonal antibodies (BD Pharmingen, San Diego, CA): PE-
labeled anti-mouse H-2Db (clone KH95), FITC-labeled anti-mouse H-2Kd (clone SF1-
1.1), PE-labeled anti-mouse H-2Dd (clone 34-2-12), and FITC-labeled anti-mouse H-2Kb 
(clone AF6-88.5) and analyzed by FACS.  
Upon immunization with rabbit red blood cells (RRBCs), αGT KO mice develop 
high titers of anti-αGal antibodies (38). Sera of mice immunized with RRBCs were 
collected to detect anti-αGal antibodies by ELISA. Briefly, 96-well polyvinyl chloride 
(PVC) ELISA plates were coated with αGal-BSA (V-Labs, Inc., Covington, LA) at a 
concentration of 5µg/mL in carbonate buffer, pH = 9.6 (Sigma, St. Louis, MO) and 
incubated overnight at 4°C. The next day, plates were washed with wash buffer (1 x PBS, 
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pH = 4.7, 0.05% Tween 20) and blocked for 2 hr with a solution of 1%BSA (Sigma) in 
carbonate buffer. Four-fold serial dilutions of primary sera were prepared using wash 
buffer, added to coated-plates and incubated for 1 hr at room temperature.  Wells were 
washed five times and a secondary antibody (horseradish peroxidase-labeled goat anti-
mouse IgG, Chemicon, Temecula, CA) diluted 1:2000 in wash buffer, was added to the 
wells and incubated for 30 mins at room temperature. Plates were then washed five times 
and substrate solution (tetramethylbenzidine and hydrogen peroxide, Pierce, Rockford, 
IL), was added for 15 mins. The reaction was stopped with 2N H2SO4 solution and 
absorbance values at 450 nm were obtained for each well using a Multiskan Spectrum 
plate reader (Thermo Labsystems, Franklin, MA).  
Animal Treatments 
Female and male, 8 to 12 weeks old, αGT KO mice were used in this study. All 
mice received 2 or 3 intraperitoneal (i.p.) immunizations of RRBCs (1 x 108 cells per 
immunization) separated by two weeks. Two efficacy studies were carried out depending 
on the sequence of the therapy and tumor inoculation, those were therapeutic and 
preventive vaccination models. In both studies two routes of tumor challenge were used, 
subcutaneous tumor challenge, s.c., and intravenous tumor challenge, i.v. using non-
irradiated B16N/V melanoma cells. All vaccinations were subcutaneously administered 
two or three times.  
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Treatment of Pre-existing Melanoma Tumors 
After RRBCs immunizations, mice received 5 x 104 of B16N/V cells injection in 
the s.c. model and 2 x 105 cells in the i.v. pulmonary model five days before vaccination. 
In the s.c. model, mice were vaccinated twice, one week apart. Treatment groups, the 
vaccination doses per mouse, and the number of animals per group are shown in Table 1. 
Mice were monitored for tumor growth and survival three times a week. Tumors were 
measured using a digital caliper and mice with necrotic tumor and/or tumor size reaching 
1000mm3 were humanely euthanized.  In the pulmonary model, mice were vaccinated 
three times, one week apart. Treatment groups, the vaccination doses per mouse, and the 
number of animals per group are shown in Table 2. In this pre-established pulmonary 
model, B16IL-15 vaccine was administered the next day. Three weeks after tumor 
implantation mice were sacrificed and lungs and tumors harvested and measured. All 
mice were treated according to the Institutional Animal Care and Use Committee 
(IACUC)-approved protocols.  
Table 1. Treatment of pre-established subcutaneous melanoma tumors. The table shows 
the different treatments administered to mice, the vaccine dose given to each mouse, and 
the number of animals per group in the pre-established subcutaneous experiment. 
  
Treatment  Number of mice per group Vaccine Dose (cells/mouse) 
No Treatment  17 No vaccine 
B16N/V Only 17 1 x 106 
B16N/V + B16IL-15 14 1 x 106 + 1 x 106 
B16αGal Only 18 1 x 106 
B16αGal + B16IL-15 23 1 x 106 + 1 x 106 
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Table 2. Treatment of pre-existing pulmonary melanoma tumors. The table shows 
the different treatments administered to mice, the vaccine dose given to each 
mouse, and the number of animals in the pre-existing pulmonary experiment. In 
this experiment, B16IL-15 vaccine was administered the day after B16N/V. 
  
Treatment  Number of mice per group Vaccine Dose (cells/mouse) 
No Treatment  15 No vaccine 
B16N/V Only 14 5 x 105 
B16N/V + B16IL-15 14 5 x 105 + 1 x 106 
B16αGal Only 15 5 x 105 
B16αGal + B16IL-15 14 5 x 105 + 1 x 106 
 
Preventive Therapy Experiments  
Important modifications were done in these sets of experiments. In addition to 
mice receiving vaccinations about five weeks prior to tumor challenge, all treatment 
groups were given the same total number of cells, 1 x 106 vaccine cells. Mice receiving 
B16αGal vaccine cells received B16N/V vaccine cells as well. In both the preventive s.c. 
and pulmonary models mice were vaccinated three times one week after the third RRBCs 
immunization. Table 3 shows treatment groups, the vaccination dose administered per 
mouse, and the number of animals per group. In the s.c. model, mice were challenged 
with 8 x 104 cells and in the i.v. model, mice received 1 x 105 tumor cells. All mice were 
treated humanely according to the IACUC-approved protocols and were monitored in the 
same way described above for the therapeutic model.    
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Table 3. Preventive therapy experiments. The table shows the different treatments 
administered to mice, the vaccine dose given to each mouse, and the number of 
animals per group in both the subcutaneous and pulmonary preventive 
experiments. 
 
  Number of mice/group 
Treatment  Vaccine Dose (cells/mouse) 
Subcutaneous 
model 
Pulmonary 
model 
No Treatment  No vaccine 
18 6 
B16N/V Only 1 x 106 
17 4 
B16N/V + B16IL-15 5 x 105 + 5 x 105 
18 8 
B16αGal + B16N/V  5 x 105 + 5 x 105 
19 8 
B16αGal + B16IL-15 5 x 105 + 5 x 105 
18 8 
 
CD8+ T Cell Purification  
CD8+ T cell purification method was optimized using varying media 
combinations for splenic processing and CD8+ T cell purification. These treatments were 
as follows: in Treatment 1, spleens were harvested and processed using Roswell Park 
Memorial Institute (RPMI) medium with 10% FBS (10%RPMI), and 0.1% Tyrode’s Salt 
Solution (TS) (St. Louis, MO) was used for CD8+ T cell purification. In Treatment 2, 
spleens were harvested and processed using 10%RPMI, and 0.1% RPMI was used for 
CD8+ T cell purification. In Treatment 3, spleens were harvested and processed using 
10%TS, and 0.1%TS was used for CD8+ T cell purification. In Treatment 4, TS was used 
for both harvesting and processing spleens and CD8+ T cell purification. CD8+ T cell 
purification was done using the Dynal® Mouse CD8 Negative Isolation kit (Invitrogen). 
Briefly, spleens were harvested using cold medium and three spleens at a time were cut 
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and mashed using a sterile plunger and sieve. Cell suspension (25mL) was passed 
through a 40µM strainer into 50-mL conical tube. NycoPrep (Greiner Bio-One, Oslo, 
Norway) (12.5mL) at room temperature was slowly added to the bottom of the tube and 
centrifuged at 600g for 20 mins at room temperature with no brakes. Cells were aspirated 
from the middle layer and washed twice with medium, using 1500rpm for 5 mins at 4°C 
for centrifugation. Splenocyte concentrations were adjusted to 1 x 108 cells/mL and CD8+ 
T cells were isolated following the manufacturer’s instructions. Purified cells were 
stained for CD3, CD4, CD8, and CD19 markers using phycoerythrin (PE)-labeled 
monoclonal antibodies (BD Pharmingen) and viability was tested using PI staining. Data 
were analyzed by FACS.  
Adoptive Transfer Experiments 
Two sets of CD8+ T cell adoptive transfer experiments were carried out. In the 
first set, CD8+ T cells donor mice were immunized three times with RRBCs two weeks 
apart. Ten days after the last RRBCs immunization mice were vaccinated three times, one 
week apart. See Table 4 for treatment groups, vaccination doses received by mice, and 
the number of animals per group. In these experiments, B16IL-15 vaccine was given the 
next day. CD8+ T cells were purified using Dynal Mouse CD8 Cell Negative Isolation 
kit, (Invitrogen) after 3 and 7 months of vaccination and intravenously transferred to 
recipient mice. Recipient mice were intravenously challenged with 1 x 105 B16N/V cells. 
At 3 months, CD8+ T cells were adoptively transferred to mice bearing 8-day tumor and 
were sacrificed two weeks after CD8+ T cells transfer. At 7 months, CD8+ T cells were 
adoptively transferred to mice bearing 7-day tumor and were sacrificed 21 days after 
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CD8+ T cells transfer. Lungs and tumors were harvested from recipient mice and weighed 
for treatment groups comparison.  
In the second set of CD8+ T cell adoptive transfer experiments, one week after the 
third RRBCs immunization, donor mice were vaccinated three times, one week apart. See 
Table 5 for treatment groups, vaccination doses received by mice, and the number of 
animals per group. In this experiment, all vaccines were given on the same day. Five 
months after the last vaccination, donor mice were sacrificed and CD8+ T cells were 
purified and adoptively transferred (i.v.) to mice bearing 6-day tumor (1 x 105 B16N/V 
cells/mouse). Recipient mice were sacrificed 21 days after CD8+ T cells transfer and 
lungs and tumors collected for measurements. 
Table 4. Adoptive transfer experiments (Set 1). The table shows the different treatments 
administered to donor mice (donors of CD8+ T cells), the vaccine dose given to each 
mouse, and the number of animals per group in the first set of adoptive transfer 
experiments where CD8+ T cells were transferred to syngeneic mice bearing tumor 3 and 
7 months after vaccination. B16IL-15 vaccine was administered the day after B16N/V 
and B16αGal vaccination. 
   
  Number of mice/ recipient group 
Treatment  Vaccine Dose (cells/mouse) 
Purification 
after 3 months 
Purification 
after 7 months 
No Treatment  No vaccine 11 13 
B16N/V + B16IL-15 5 x 105 + 1 x 106 12 10 
B16αGal + B16N/V  5 x 105 + 5 x 105 14 7 
B16αGal + B16IL-15 5 x 105 + 1 x 106 12 13 
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Table 5. Adoptive transfer experiments (Set 2). The table shows the different 
treatments administered to donor mice (donors of CD8+ T cells), the vaccine dose 
given to each mouse, and the number of animals per group in the second set of 
adoptive transfer experiments where CD8+ T cells were transferred to syngeneic 
mice bearing tumor 5 months after vaccination. 
 
Treatment  Number of mice per group Vaccine Dose (cells/mouse) 
No Treatment  7 No vaccine 
B16N/V + B16IL-15 7 1 x 106+ 1 x 106 
B16αGal + B16N/V  7 1 x 106+ 1 x 106 
B16αGal + B16IL-15 7 1 x 106+ 1 x 106 
 
In Vitro CFSE Labeling and Proliferation of Lymphocytes 
To measure the effects of IL-15 on CD8+ T cells proliferation, in vitro CFSE 
labeling technique was set up using CellTrace™ CFSE Cell Proliferation kit (Invitrogen). 
Spleens were harvested and processed using TS as described above. Lymphocytes 
concentration was adjusted to 5 x 107 cells/mL and 1 x 108 cells/mL and cells were 
stained with CFSE at a final concentration of 5µM. Cells were incubated at room 
temperature with continuous mixing and the reaction was stopped after five mins with 
cold FBS. Cells were washed three times with TS and cultured using either X-Vivo 
15TM (Lonza) or RPMI 1640 complete medium at two different concentrations, 1.5 x 106 
cells/mL and 2.5 x 106 cells/mL in 24-well plates. CD3/CD28 beads (Dynabeads® 
Mouse CD3/CD28 T Cell Expander, Invitrogen) were used for the proliferation of mouse 
T cells following manufacturer’s instructions. Recombinant human IL-2 (rhIL-2) was 
added at a concentration of 10 IU/mL (R & D Systems, Minneapolis, MN). Cell cultures 
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were prepared in a final volume of 2mL and cells were incubated at 37°C and 5% CO2 
for three and four days. The same method was followed to trace the proliferation of CD8+ 
T cells.  
Next, CD8+ T cells were purified from B16αGal + B16N/V and B16αGal + 
B16IL-15-vaccinated mice 2 months after vaccination, labeled with CFSE at a final 
concentration of 5uM, and cultured at a concentration of 1.5 x 106 cells per mL in RPMI 
complete medium with 5 x 104 irradiated B16N/V, irradiated B16N/V and IL-2 (at a 
concentration of 10 IU/mL), or irradiated B16IL-15 cells. Cell cultures were prepared in 
a final volume of 2mL in 24-well plates and cells were incubated at 37°C and 5% CO2 for 
six days.  
In Vivo Proliferation of Transferred CD8+ T Cells  
CD8+ T cells were purified from mice vaccinated with B16αGal + B16IL-15 and 
B16αGal + B16N/V vaccines as described above. Purified CD8+ T cells’ concentration 
was adjusted to 5 x 107 cells/mL and labeled with CFSE at a final concentration of 5uM 
as described above. CFSE-labeled CD8+ T cells (3 x 106) were intravenously transferred 
to recipient mice. The next day, Day 0, mice were intradermally vaccinated with 1 x 106 
irradiated B16N/V melanoma cells. On days 3 and 6, recipient mice were humanely 
sacrificed and non-draining lymph nodes, draining lymph nodes, and spleens were 
harvested, processed, and lymphocytes were labeled with anti-CD3, -CD4, -CD8, and -
CD19 monoclonal antibodies and analyzed by FACS. This experiment was repeated with 
some modifications: CD8+ T cells were not only purified from two groups but from non-
vaccinated mice, B16N/V-, B16αGal + B16N/V-, and B16αGal + B16IL-15-vaccinated 
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mice, labeled with CFSE, and intravenously transferred and lymphocytes were purified 
and analyzed after 6 days of stimulation.  
Statistical Analysis 
GraphPad Prism software was used for statistical analysis. An overall F-test was 
performed to test the null hypothesis of no difference between the treatment groups. Log-
rank test was performed to compare animal survival curves. In addition, Student t-test 
was used to perform the pairwise comparisons of tumor and lung weights between the 
groups, and Tukey’s adjustment was used to correct for multiple comparisons.  
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RESULTS 
Section 1: Description of the plasmid, cell lines, and animal 
model.  
This section describes the cell lines, vaccine preparations, and the animal model 
used in this study.  
The cell line B16F0 melanoma was used in this study. These cells were 
transfected with a plasmid expressing human IL-15 to generate the B16IL-15 cells. Six 
clones of B16IL-15 were pooled, irradiated, and used for vaccination in combination with 
B16 melanoma cells expressing the αGal epitope (B16αGal) and naïve B16 melanoma 
cells that did not express the αGal epitope (B16N/V). Mice knocked out for the αGT 
enzyme were used in this study.  
Production of B16IL-15 Cell Line 
B16F0 cells were transfected with human IL-15, hereafter B16IL-15, and further 
screened for IL-15 production.  A total of 120 clones were obtained and the production of 
IL-15 in the culture supernatants was tested using Human IL-15 ELISA kit (BD 
OptEATM,). IL-15 production of each clone was compared to IL-15 production of a 
mixed population of B16IL-15 cells. Clones with higher IL-15/WST-1 ratios and thus 
higher IL-15 production than the mixed population were chosen for further screening. 
WST-1 reagent is used to measure viable cells allowing the calculation of IL-15 
production per cell and thus making the data of different clones comparable. From 120 
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clones, 15 potential clones were chosen and IL-15 production of these clones was 
detected after 24, 48, and 72 hr of incubation (Figure 1).  
Of these potential clones, 6 clones were chosen for future experiments. Selection 
was based on IL-15 production rate, level, and timing. For example, Clones 7 and 9 
produced IL-15 at an increasing rate compared to other clones, whereas Clone 13 was 
chosen because it produces IL-15 at a highest rate at all times. Clone 2 was discarded due 
to its low IL-15 production rate. See Figure 1. As a result, Clones 5, 7, 9, 10, 11, and 13 
were chosen for further experiments.  
 
Figure 1. IL-15 production by B16IL-15 clones.  
A total of 3000 cells were cultured in 200µL complete medium in 96-well 
plates. Each clone was represented in triplicates. Three plates were 
prepared for the three different incubation times: 24 hr, 48 hr, and 72 hr. 
Wells were checked for media every day and for ELISA 100µL of 
supernatant was used.  
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B16 Melanoma Cell Vaccines 
B16F0 cells (named here B16N/V), B16αGal, and B16IL-15 melanoma cells were 
grown in complete medium containing 1% Ciprofloxacin (1mg/mL). Five weeks after 
removal of antibiotic, cells received 200Gy of γ-irradiation and were stored in liquid 
nitrogen using freezing medium (90% DMSO and 10% FBS). B16IL-15 clones were 
grown separately and then pooled at the time of irradiation. For quality control purposes 
each vaccine preparation (lot) was tested for Mycoplasma using MycoSensorTM PCR 
assay kit from Stratagene.  A representative example is shown in Figure 2A. All cells and 
vaccine lots used for the experiments were Mycoplasma free.  
 
Figure 2. B16 melanoma cell vaccines.   
A. Mycoplasma testing.  MycoSensorTM PCR assay kit from Stratagene 
was used and manufacturer’s instructions were followed. B. Viability of 
cells. Propidium iodine (PI) solution (5µL) was added to 1 x 106 cells and 
data were analyzed by FACS. PI dye stains dead cells. In each panel the 
percentage of viable cells before vaccination is shown.  
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The viability of all vaccine lots and B16 cells used for tumor challenge (B16N/V 
tumor cells) was tested for each experiment by the incorporation of propidium iodine (PI) 
florescent dye. About 45.0% to 75.0% of vaccine cells were viable using PI staining. 
Figure 2B shows a representative example indicating that 93.5% of tumor cells were 
viable before tumor challenge, and the viability of vaccine cells was 49.6%, 74.7%, and 
64.0% for B16N/V, B16αGal, and B16IL-15 vaccines, respectively. 
B16N/V cells which are derived from C57BL/6 melanoma do not express αGal 
epitopes due to down-regulation of the αGT gene (95). Nevertheless, αGal expression of 
transduced and non-transduced cells was tested for each vaccine lot using IB4-FITC 
lectin. This lectin has been shown to specifically bind to αGal epitopes (96). About 
65.0% to 80.0% of B16αGal vaccine cells expressed αGal epitopes, similar to the level of 
αGal expression of vaccines previously used by investigators at our laboratory (39, 43) 
(Figure 3). 
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Figure 3.  Expression of αGal epitopes by vaccine cells.  
Cells (2 x 106) were stained with 5µL of IB4-FITC lectin. After 30 mins of 
incubation at 4°C, cells were washed and analyzed by FACS. A. B16F0 
melanoma cells transduced with a vector encoding αGT gene (referred to 
in manuscript as B16αGal). B. B16F0 melanoma cells, nontransduced 
(referred to in manuscript as B16N/V). 
 
B16IL-15 clones were grown separately and then pooled at the time of irradiation 
to prevent the outgrowth of any particular clone. After irradiation cells were tested for IL-
15 production using Human IL-15 ELISA kit. We tested IL-15 production of the vaccine 
lots after three 48 hr-intervals. Cells were incubated in triplicates in three different 96-
well plates. After 48 hr of incubation at 37°C and 5% CO2, cells in the first plate were 
tested for IL-15 production. On that same day, the medium was changed for the second 
and third plates and plates were incubated for an additional 48 hr. After the second 48 hr-
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incubation interval (four days of the start date of the experiment), cells of the second 
plate were tested for IL-15 production while the medium of the third plate was changed. 
The cells of the third plate were tested for IL-15 production after a third 48 hr-interval 
(six days after the start of the experiment). This assay was designed to test the duration of 
IL-15 production by B16IL-15 cell clones. On average, this is a result of triplicates of 
different cell concentrations, B16IL-15 cells produced 55.5 x 10-4 pg/mL per cell after the 
first 48 hr-interval. In the second interval, the mean production of IL-15 per cell was 22.7 
x 10-4 pg/mL. In the final 48 hr-incubation period, the cells produced a mean of 68.8 x 10-
4 pg/mL per cell (Figure 4). B16N/V vaccine cells did not produce any detectable IL-15.     
 
Figure 4. IL-15 production by B16IL-15 vaccine. 
B16IL-15 vaccine cells were cultured at five different concentrations. 
Each concentration was evaluated in triplicates and 100µL of supernatant 
was harvested from each well for ELISA. Cell numbers were determined 
using WST-1 reagent: 100µL of fresh medium was added to the cells and 
then 10µL of WST-1 reagent. Cells were incubated at 37°C and 5% CO2 
and absorbance was measured at 440nm every 30 mins during incubation. 
Results shown here are calculated after three hours of incubation with 
WST-1 reagent.  
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The αGT KO Mouse Model  
Animals used in this study were αGT KO mice originally purchased from Dr. J.B. 
Lowe (University of Michigan) (40). The αGal expression in these mice was tested by 
FITC-labeled IB4 staining using peripheral blood lymphocytes. Figure 5A shows that 
these cells are negative for αGal epitopes. Lymphocytes were also used to determine the 
haplotypes of these mice. Cells were double stained with anti-H-2Kb FITC and anti-H-
2Dd PE monoclonal antibodies and anti-H-2Kd FITC and anti-H-2Db PE monoclonal 
antibodies (data not shown). Cells expressed both H-2Kb (Figure 5B) and H-2Db 
molecules and did not express H-2Kd or H-2Dd molecules (Figure 5B).  
 
Figure 5. Phenotype of the α1,3-galactosyltransferase knock out (αGT KO) 
mice.  
A. Expression of αGal epitopes in αGT KO mice. Peripheral blood 
lymphocytes isolated from αGT KO mice or wild type mice (positive 
control) were stained with lectin and 7-AAD and analyzed by FACS. B. 
Mice used in this study were homozygous for H-2b/b haplotype. Peripheral 
blood lymphocytes were double stained with anti-H-2Kb FITC + anti-H-
2Dd PE monoclonal antibodies and anti-H-2Kd FITC + anti-H-2Db PE 
monoclonal antibodies (data not shown).  
 
Humans produce natural antibodies that recognize the αGal epitope. These 
antibodies are often produced only in low titers in the αGT KO mouse (97, 98). In order 
to increase the anti-αGal Abs to similar levels found in humans, animals were immunized 
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with RRBCs. These cells express large quantities of αGal epitopes and immunization 
with RRBCs induces anti-αGal Abs in most animals. Figure 6 shows a representative 
example of 12 animals used in this study immunized with RRBCs. Eleven out of 12 
animals produced high titers of anti-αGal Abs.  
 
Figure 6. Anti-αGal Ab production in the αGT KO mice after RRBCs 
immunizations.  
Mice received three RRBCs immunizations two weeks apart. Blood was 
collected from each mouse two weeks after the last RRBCs immunization. 
Four serum dilutions were prepared for each mouse sample and tested in 
triplicates for anti-αGal IgG antibodies by ELISA. Red lines represent 
positive control sera and blue lines represent negative control sera.  
 
Section 2: Treatment of B16 melanoma by the combination 
vaccine approach in αGT KO mice 
This section describes the murine melanoma models utilized to test if the 
combination therapy consisting of B16αGal plus B16IL-15 vaccines would improve the 
treatment of melanoma compared to the conventional vaccine consisting of B16αGal 
only.  
The combination therapy was tested in two melanoma models: the therapeutic 
model where mice were first challenged with tumor subcutaneously or intravenously and 
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then vaccinated, and the preventive model where mice were first vaccinated and then 
challenged with tumor cells either subcutaneously or intravenously.   
Treatment of Pre-existing Melanoma Tumors  
Vaccination with B16BL6 melanoma cells expressing the αGal epitope had 
previously shown significant reduction in the pulmonary tumors burden as well as 
significant enhancement of animal survival when compared to mice receiving B16BL6 
vaccination only and no vaccination (43). In order to test if the addition of IL-15 to the 
vaccination regimen would increase the efficacy of the B16αGal vaccine, the stringency 
of the model was increased by reducing the therapeutic vaccine dose and by increasing 
the tumor implantation dose. We administered half of the B16αGal dose previously 
shown to be therapeutic (5 x 105 cells/mouse) and increased the tumor dose by two folds 
(2 x 105 cells per mouse). Under these conditions the efficacy of B16αGal vaccine was 
compromised in order to determine if the addition of B16IL-15 would increase vaccine 
efficacy.  
As shown in Figure 7, treatment with B16αGal in combination with B16IL-15 
significantly reduced the pulmonary melanoma metastasis burden compared to animals 
receiving no treatment (ANOVA p = 0.029, columns comparison by t test p = 0.002). The 
addition of B16IL-15 to the B16αGal vaccine trended towards increasing the efficacy 
against pre-existing tumors, although this difference was not statistically significant 
(columns comparison by t test p = 0.057).  We compared all treatment groups using 
Tukey’s and t tests.  Results of the statistical analysis are found in Table 6.   
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The data suggest that the addition of B16IL-15 seems to provide a slight 
therapeutic benefit to the conventional B16αGal vaccine under the experimental 
conditions employed.  
 
Figure 7. Treatment of pre-existing pulmonary melanoma.  
Mice received 2 intraperitoneal RRBCs immunizations (1 x 108 
cells/mouse), subsequently they were challenged with 2 x 105 B16N/V 
tumor cells intravenously. Five days later, they either received no 
vaccination or received 3 subcutaneous vaccinations. B16IL-15 vaccine 
cells were administered the day following B16N/V and B16αGal 
vaccinations. About two weeks after tumor challenge mice were humanely 
sacrificed and lungs and tumors harvested and weighed (weights are 
shown) for each group of mice. See Materials and Methods for the number 
and type of vaccine cells administered to mice in each group (Table 2).  
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Table 6: Multiple columns comparison using Tukey’s and t tests. Treatment of pre-existing 
pulmonary melanoma. After 2 i.p. RRBCs immunizations, mice were challenged i.v. with 
2 x 105 tumor cells. Five days later they received either no vaccination or 3 s.c. 
vaccinations. About two weeks later, mice were sacrificed and their lungs and tumors 
weighed. The table shows columns comparison of the weights and highlighted are the 
significant p values obtained by t-test. See Materials and Methods for more details (Table 
2). 
 
Multiple columns comparison 
Significance by 
Tukey's test Student t test 
No Treatment vs B16N/V No 0.562 
No Treatment vs B16N/V +  
B16IL-15 No 0.268 
No Treatment vs B16αGal No 0.053 
No Treatment vs B16αGal +  
B16IL-15 Yes 0.002 
B16N/V vs B16N/V + B16IL-15 No 0.619 
B16N/V vs B16αGal No 0.230 
B16N/V vs B16αGal + B16IL-15 No 0.017 
B16N/V + B16IL-15 vs B16αGal No 0.524 
B16N/V + B16IL-15 vs B16αGal +  
B16IL-15 No 0.053 
B16αGal vs B16αGal + B16IL-15 No 0.057 
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We asked the question whether this observation would be repeated in a more 
difficult model which is the treatment of pre-existing subcutaneous melanoma. Very few 
strategies thus far have demonstrated convincingly effective treatment of pre-existing 
subcutaneous B16 melanoma tumors (99). In this experiment, optimal vaccine doses (1 x 
106 cells/mouse) were administered 5 days after tumor implantation.  Under these 
conditions we demonstrated that the addition of B16IL-15 to the conventional B16αGal 
vaccine significantly increased the survival of vaccinated mice receiving the combination 
therapy (Figure 8, Log Rank test p = 0.008). In this experiment, the B16αGal vaccine did 
not increase the survival of mice compared to un-treated control mice as previously 
shown.  Currently it is unclear why this was the case. One explanation could be that the 
administration of vaccines was performed 5 days after tumor implantation. Previous 
publications using B16 cells expressing GM-CSF demonstrated that the vaccine efficacy 
varies tremendously depending on the timing of administration after tumor implantation. 
In this experiment, vaccines were administered 5 days after tumor implantation which is 
2 days later than our prior work (43).  
As before, multiple comparisons were made using Log Rank test (Table 7). As 
shown in the table the only treatment that significantly increased animal survival 
compared to un-treated mice was the combination therapy, B16αGal + B16IL-15 vaccine.  
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Figure 8. Animal survival in the pre-established subcutaneous melanoma 
model.  
Mice received 3 intraperitoneal RRBCs immunizations (1 x 108 
cells/mouse). Ten days later, they were challenged with 5 x 104 B16N/V 
tumor cells subcutaneously. Five days later, mice received either no 
vaccination or were subcutaneously vaccinated twice, one week apart. 
Tumor volume was measured and mice were monitored three times a 
week. See Materials and Methods for the number and type of vaccine cells 
administered to mice and the number of animals per group (Table 1). P = 
0.744 for No Treatment vs B16αGal; p = 0.493 for B16αGal vs B16N/V; p 
= 0.008 for B16αGal vs B16αGal + B16IL-15; p = 0.001 for No Treatment 
vs B16αGal + B16IL-15.   
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Table 7. Multiple sets comparison using Log-Rank test. Pre-established 
subcutaneous melanoma model. Ten days after the third RRBC 
immunization, mice were challenged s.c. with 5 x 104 tumor cells. Five days 
later they received either no vaccination or 2 s.c. vaccinations. Tumor 
volume was measured and mice were monitored three times a week. The 
table shows columns comparison of animal survival 30 days after tumor 
challenge and highlighted are the significant p values. See Materials and 
Methods for more details (Table 1). 
 
Multiple columns comparison Log Rank  test 
No Treatment vs B16N/V 0.273 
No Treatment vs B16N/V + B16IL-15 0.083 
No Treatment vs B16αGal 0.744 
No Treatment vs B16αGal + B16IL-15 0.001 
B16N/V vs B16N/V + B16IL-15 0.500 
B16N/V vs B16αGal 0.493 
B16N/V vs B16αGal + B16IL-15 0.065 
B16N/V + B16IL-15 vs B16αGal 0.178 
B16N/V + B16IL-15 vs B16αGal +  
B16IL-15 
0.312 
B16αGal vs B16αGal + B16IL-15 0.008 
 
Preventive Therapy Experiments  
We started with the pre-established melanoma model to determine whether or not 
B16IL-15 addition to the established system would increase the efficacy of the B16αGal 
treatment. However, it was not possible to determine a convincing difference among the 
groups in both experiments and since B16 melanoma is such an aggressive tumor model, 
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we decided to test the hypothesis in a less stringent model system, which is the 
preventative vaccination setting. In these experiments animals were vaccinated with 
whole cell vaccines and subsequently challenged with tumor. In addition another 
modification was introduced to the vaccination modality. In the previous experiments, 
described above, treatment groups received different cell doses of vaccines, but in the 
preventive experiments, mice received the same total number of vaccine cells in all 
treatment groups and mice receiving B16αGal vaccine received B16N/V vaccine cells as 
well to compensate for the B16IL-15 vaccine cells given to mice receiving B16αGal + 
B16IL-15 vaccine. Therefore, after eliciting anti-αGal antibodies by RRBCs 
immunizations, mice were either subcutaneously or intravenously challenged with 
B16N/V tumor cells about five weeks after the third vaccination. In the subcutaneous 
melanoma experiment, mice were monitored for over 65 days after tumor challenge and 
tumor measurements were recorded three times a week. There were 5 treatment groups as 
mentioned in the Materials and Methods section (Table 3): non-vaccinated mice (No 
Treatment group), mice receiving 1 x 106 cells of B16N/V vaccine cells alone, mice 
receiving 5 x 105 cells of B16N/V and 5 x 105 B16IL-15 vaccine cells, mice receiving 5 x 
105 B16αGal and 5 x 105 B16N/V vaccine cells, or mice receiving 5 x 105 B16αGal and 5 
x 105 B16IL-15 vaccine cells. All vaccinated mice showed significantly higher animal 
survival and reduced tumor growth when compared to non-vaccinated mice (Figure 9). In 
addition, there was no significant difference in animal survival or tumor growth of mice 
vaccinated with B16N/V alone and B16αGal + B16N/V, p = 0.235. Animal survival after 
67 days of B16N/V tumor challenge was significantly higher in mice vaccinated with 
B16αGal + B16IL-15 than in mice vaccinated with B16αGal + B16N/V cells, p = 0.021. 
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Figure 9. Animal survival in the preventive subcutaneous melanoma model.  
Mice received 3 intraperitoneal RRBCs immunizations (1 x 108 
cells/mouse). ). One week later, mice received no treatment or were 
vaccinated three times, 2 weeks apart. Five weeks later, mice were 
subcutaneously challenged with 8 x 104 B16N/V tumor cells. Tumor 
volume was measured and mice were monitored three times a week. See 
Materials and Methods for the number and type of vaccine cells 
administered to mice and the number of animals per group (Table 3). P = 
0.001 for No Treatment vs B16αGal + B16N/V; p = 0.235 for B16N/V vs 
B16αGal + B16N/V; p = 0.021 for B16αGal + B16N/V vs B16αGal + 
B16IL-15; p < 0.0001 for No Treatment vs B16αGal + B16IL-15. 
 
In the first preventive pulmonary experiment, male mice were sacrificed less than 
4 weeks after tumor challenge as expected. Mice receiving the combination therapy, 
B16αGal + B16IL-15 vaccines, had significantly less tumor load than mice receiving 
B16αGal + B16N/V vaccines, p = 0.045. In addition, mice receiving B16αGal + B16N/V 
vaccine showed significantly less tumor burden than mice receiving B16N/V only, p = 
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0.033. In this experiment, mice receiving no vaccination started dying from metastatic 
tumor 3 days before all mice in other groups. Thus, No Treatment group was eliminated 
from our data analysis. Furthermore, females of all treatment groups, except the No 
Treatment group, did not take the tumor as expected. They stayed alive with no signs of 
health deterioration due to tumor for about two months after tumor challenge. Therefore, 
females’ data were excluded from further analysis (Figure 10). This experiment was 
repeated but different results were obtained. As in the preventive subcutaneous 
experiment, all vaccinated mice showed anti-tumor immunity against B16N/V melanoma 
cells but with no significant differences between any of the vaccinated groups. Tumor 
burden was only significantly less in vaccinated mice of each group when compared to 
mice of the No Treatment group, p < 0.05.  
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Figure 10. Metastatic potential of B16N/V melanoma cells in the preventive 
pulmonary model. 
Mice received 3 intraperitoneal RRBCs immunizations (1 x 108 
cells/mouse). One week later, mice received no treatment or were 
vaccinated three times, 2 weeks apart. Five weeks later, mice were 
intravenously challenged with 1 x 105 B16N/V tumor cells intravenously. 
Three weeks after tumor challenge mice were humanely sacrificed and 
lungs and tumors harvested and weighed (weights are shown) for each 
group of mice. See Materials and Methods for the number and type of 
vaccine cells administered to mice and the number of animals per group 
(Table 3). P = 0.033 for B16N/V vs B16αGal + B16N/V; p = 0.045 for 
B16αGal + B16N/V vs B16αGal + B16IL-15; p = 0.016 for B16N/V vs 
B16αGal + B16IL-15.  
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Section 3: Setup experiments for CD8+ T cell purification 
The purification of CD8+ T cells was one of the crucial techniques used in this 
study. In order to recover CD8+ T cells from mice with high viability and percent yield, 
CD8+ T cell purification technique was optimized in several trials explained below.  
CD8+ T Cell Purification  
To test if IL-15 will induce the proliferation and maintenance of long term 
memory CD8+ T cells, the technique for CD8+ T cell purification needed to be perfected. 
These initial experiments demonstrated effective purification of CD8+ T cells from non-
vaccinated animals and this protocol was used in the subsequent experiments.  
CD8+ T cells were negatively isolated by magnetic purification from splenocytes 
using Dynal® Mouse CD8 Negative Isolation kit (Invitrogen) and purification efficacy 
was determined by FACS staining with anti-CD3, -CD4, -CD8, and –CD19 monoclonal 
antibodies. As described in Materials and Methods section, four treatments were tested 
before finalizing the best conditions for this procedure. In the first trial, Treatments 3 and 
4 gave the best purification efficacy: 65.7% CD3, 84.9% CD8, and 81.2% CD3, 81.1% 
CD8, respectively, as well as the highest viability of cells using PI staining: 83.4% and 
91.8% viable cells, respectively. Figure 11 shows all results of Trial 1. The yield of CD8+ 
T cells using Treatments 1 and 2 was very low and there were not enough cells to stain 
for CD3, CD4, and CD19 markers. As a result, only Treatments 3 and 4 were chosen for 
further development. The purification efficacy of these two treatments did not differ 
significantly in any of the subsequent testing, however using only TS for harvesting and 
processing spleens and purifying CD8+ T cells showed slightly better purification efficacy 
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than Treatment 3 (Figure 12). Viability was also comparable for both treatments: cells 
treated with Treatment 3 were 94.1% viable whereas cells treated with Treatment 4 were 
96.9% viable in Trial 3.  Thus, TS (Treatment 4) was chosen for the second and third 
adoptive transfer experiments.  
Figure 12 shows the results of CD8+ T cell purification of the third adoptive 
transfer experiment, the transfer of CD8+ T cells five months after vaccination (see 
below). On average more than 83.0% of T cells transferred to donor mice were 
CD3+CD8+ cells and the % yield of CD8+ T cells was more than 100% of expected yield.  
 
Figure 11. CD8+ T cell purification Trial 1.  
Spleens were processed and CD8+ T cells were purified from spleens using 
different media combinations. See Materials and Methods section for 
details. Cells were stained with anti-CD3, -CD4, -CD8, and -CD19 using 
PE-labeled monoclonal antibodies and data were analyzed by FACS.   
 
 
 49
 
Figure 12. CD8+ T cell purification Trial 3.  
Spleens were processed and CD8+ T cells were purified using Treatments 
3 and 4 conditions in Trial 2 and Trial 3. See Materials and Methods for 
detailed description of the treatments. TS (Treatment 4) was chosen to 
process spleens and purify CD8+ T cells for the second and third adoptive 
transfer experiments. The average efficacy of purifying CD8+ T cells from 
the four groups of mice: No Treatment, B16N/V + B16IL-15, B16αGal + 
B16N/V, and B16αGal + B16IL-15 in the third adoptive transfer 
experiment is also shown. Cells were stained with anti-CD3, -CD4, -CD8, 
and -CD19 monoclonal antibodies and data were analyzed by FACS. 
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Section 4: Adoptive transfer experiments to treat pre-existing 
pulmonary melanoma.  
In addition to detecting any effects of combining IL-15 with B16αGal vaccine on 
the treatment and prevention of tumor, the effects of IL-15 on the cytotoxic activity of 
CD8+ T cells were also tested in adoptive transfer experiments. Purified CD8+ T cells 
were obtained from vaccinated and non-vaccinated mice and adoptively transferred to 
mice bearing pulmonary tumors.  
The Experimental Design of the Adoptive CD8+ T Cell Transfer 
Experiments  
It was shown previously that CD8+ T cells adoptively transferred from αGT KO 
mice vaccinated with B16BL6 cells expressing the αGal epitope recognized B16BL6 
tumor cells when transferred two weeks after the last vaccination to syngeneic αGT KO 
mice bearing 5-day B16BL6 melanoma tumors (43). To test if the introduction of IL-15 
to the system will enhance the maintenance of long-term memory CD8+ T cells as 
reported in literature, CD8+ T cells were adoptively transferred from non-vaccinated and 
vaccinated mice to recipient mice bearing tumors. Purified CD8+ T cells were transferred 
after 3, 5, and 7 months of vaccination (Figure 13).  
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Figure 13. The experimental design of adoptive transfer experiments.  
Donor mice (donors of CD8+ T cells) receive the standard immunization 
with RRBCs, then are vaccinated or not. After resting for several months, 
donor mice are sacrificed and their spleens harvested. CD8+ T cells are 
then purified from spleens and intravenously transferred to mice bearing 
tumor. Recipient mice are monitored and around two weeks after tumor 
challenge they start to show signs of discomfort due tumor burden. The 
experiment is then terminated and the lungs of recipient mice are 
harvested and weighed. 
 
Transfer of CD8+ T Cells from Vaccinated Mice to Recipient 
Mice Bearing Pulmonary Tumors  
Mice were vaccinated as explained above and rested for several months to test for 
the induction of long-term memory cells after vaccination. In the first experiment, CD8+ 
T cells were purified 3 months after vaccination and intravenously transferred to recipient 
mice bearing 8-day tumor. Recipient mice were humanely euthanized and lungs and 
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tumors harvested and weighed for groups’ comparison. The only significant difference 
obtained was between mice that received no CD8+ T cells (No Transfer group) and mice 
receiving CD8+ T cells from donor mice vaccinated with B16αGal + B16IL-15 cells, p = 
0.024 (Figure 14).  In this experiment and before transfer, purified CD8+ T cells clumped 
upon resuspending with Dulbecco’s Phosphate Buffered Saline 1X (DPBS) and thus the 
viability of the cells was compromised. Less than 50.0% of the cells were viable before 
transfer; this was indicated by trypan blue exclusion.   
 
Figure 14. CD8+ T cells adoptively transferred to syngeneic mice after 3 
months of vaccination.  
CD8+ T cells were intravenously transferred from vaccinated and non-
vaccinated mice to mice bearing 8-day tumor three months after the last 
vaccination. Fourteen days after CD8+ T cell transfer, lungs and metastatic 
tumors were collected and weighed for comparison. See Materials and 
Methods for detailed description of the treatment groups and number of 
vaccine cells administered (Table 4). The only significance obtained was 
when comparing B16αGal + B16IL-15 with No Transfer group, p = 0.024.   
 
In conclusion, the results obtained were less than optimal mostly due to the poor 
viability of transferred cells. In order to overcome this technical difficulty, different CD8+ 
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T cell purification procedures were tested and the optimized procedure was utilized in the 
following experiments.  
The major change in the purification procedure was the use of TS instead of PBS. 
Thus, for the second and third experiments, TS was used to process spleens, purify and 
transfer CD8+ T cells (see CD8+ T Cells Purification in Methods section).  
Typically, pulmonary melanoma metastasis experiments are terminated when 
animals start to show signs of discomfort due to tumor burden. In the adoptive transfer 
experiment shown in Figure 15, mice receiving no CD8+ T cells (No Transfer group) 
started to show disease symptoms, therefore the entire experiment was terminated. 
Unfortunately, animals receiving T cells from all other groups had very small tumors for 
which it was not possible to determine a statistically significant difference in the tumor 
burden among the groups. The only significant difference seen in this adoptive transfer 
experiment was between mice receiving no CD8+ T cells and any other group (Figure 15). 
We performed a literature search to explain the reduction in melanoma tumors when 
CD8+ T cells were transferred from non-vaccinated mice to syngeneic mice. It was 
demonstrated that in fact these cells induce a transient state of “immune-protection” that 
is subsequently lost. Only animals receiving cells from vaccinated mice showed long-
term protection from melanoma (Dr Hyan Levitsky, personal communication, Cancer 
Vaccine Consortium Meeting 2006). Consequently, it was concluded that this T cell 
transfer experiment was prematurely terminated since we based our end-point on the 
health status (tumor burden) of animals receiving no CD8+ T cells (No Transfer group).  
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The adoptive T cell transfer experiment was repeated and based on our experience 
with the previous experiment it was terminated when mice receiving CD8+ T cells from 
non-vaccinated donor mice showed signs of health deterioration due to tumor metastases. 
The group of animals receiving no T cell transfer was included and used as control for 
tumor take.  
Results from this experiment showed that there was a significant reduction in 
tumor burden when comparing mice receiving either B16αGal + B16N/V or B16αGal + 
B16IL-15 with mice receiving no CD8+ T cells, No Transfer group, p = 0.006 and p = 
0.005, respectively. There was no significant difference in tumor burden between mice 
receiving B16αGal + B16IL-15 and mice receiving B16αGal + B16N/V, p = 0.885 or 
when comparing the later groups with mice receiving CD8+ T cells from non-vaccinated 
mice. As in a previous experiment, females did not develop tumor upon challenge with 
B16N/V tumor cells and thus their data were excluded from the analysis. Figure 16 
shows only male mice data.  
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Figure 15. CD8+ T cells adoptively transferred to syngeneic mice after 7 
months of vaccination.  
CD8+ T cells were intravenously transferred from vaccinated and non-
vaccinated mice to mice bearing 7-day tumor 7 months after the last 
vaccination. Twenty one days after CD8+ T cells transfer, lungs and 
metastatic tumors were collected and weighed for comparison. See 
Materials and Methods for detailed description of the treatment groups and 
number of vaccine cells administered (Table 4). There was a significant 
reduction in tumor burden when comparing any treatment group with the 
No Transfer group, p < 0.05. 
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Figure 16. CD8+ T cells adoptively transferred to syngeneic mice after 5 
months of vaccination.  
CD8+ T cells were intravenously transferred from vaccinated and non-
vaccinated mice to mice bearing 6-day tumor 5 months after the last 
vaccination. Twenty one days after CD8+ T cells transfer, lungs and 
metastatic tumors were collected and weighed for comparison.  See 
Materials and Methods for detailed description of the treatment groups and 
number of vaccine cells administered (Table 5). The only significance 
obtained was when comparing either B16αGal + B16N/V (p = 0.006) or 
B16αGal + B16IL-15 (p = 0.005) with the No Transfer group.  
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Section 5: Setup experiments for T cell proliferation and tracking 
by CFSE 
The CFSE dye was used to label T cells to monitor their proliferation in vitro and 
to locate cells in vivo. This technique was important to set up to detect any effects of IL-
15 on the proliferation of CD8+ T cells.  
In Vitro CFSE Labeling and Proliferation of Lymphocytes 
In vitro CFSE labeling of lymphocytes was setup in order to detect if the in vivo 
administration of vaccines expressing IL-15 would enhance the proliferative potential of 
CD8+ T cells. Several test conditions were employed. Lymphocytes were isolated, stained 
with CFSE at a final concentration of 5µM and activated using CD3/CD28 beads. Cells 
were stained with CFSE at 5 x 107 cells/mL and 1 x 108 cells/mL and cultured using two 
different media, RPMI 1640 complete medium and X-Vivo, at two different 
concentrations, 1.5 x 106 cells/mL and 2.5 x 106 cells/mL in 24-well plates and in a final 
volume of 2mL. Cultures were incubated for 3 and 4 days at 37°C and 5% CO2. Cells 
under all conditions had successfully proliferated and proliferation was efficiently 
detected by CFSE labeling at days 3 and 4 (Figure 17). Some samples showed 93.0% 
proliferation and 5 to 6 cell divisions. However, the viability of cells cultured with X-
Vivo was relatively low compared with cells cultured with RPMI 1640 complete 
medium: 52.0% and 73.0% viable cells, respectively. Thus, RPMI 1640 was chosen for 
further CFSE-labeling assays. The viability of cells was measured using 7-Amino-
actinomycin D (7-AAD) viability staining solution from BD Pharmingen.  
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Figure 17. In vitro CFSE labeling and proliferation of lymphocytes.  
Lymphocytes were stained with CFSE at a final concentration of 5µM and 
cultured with RPMI 1640 complete medium or X-Vivo at 1.5 x 106 
cells/mL and 2.5 x 106 cells/mL. After 3 and 4 days of culture, cells were 
harvested and washed once with TS and samples were analyzed by FACS. 
Shown here are the FACS results for cells stained with CFSE at 5 x 107 
cells/mL concentration, cultured at 1.5 x 106 cells/mL in RPMI 1640 
complete medium for four days. A. Cells cultured without CD3/CD28 
activating beads. B. Cells cultured with CD3/CD28 activating beads.  
 
The next step was to CFSE label and detect the proliferation of purified CD8+ T 
cells in vitro. CD8+ T cells were labeled with 5µM CFSE at a concentration of 5 x 107 
cells/mL and cultured at 1.5 x 106 cells/mL in a final volume of 2mL. After three days in 
culture, cells were harvested, washed once with TS, and labeled with anti-CD3, -CD4, -
CD8, and -CD19 monoclonal antibodies and data were analyzed by FACS. Almost 
80.0% of the cells divided of which 41.0% were viable (Figure 18).  
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Figure 18. In vitro CFSE labeling and proliferation of CD8+ T cells.  
CD8+ T cells were stained with 5µM CFSE at a concentration of 5 x 107 
cells/mL and then cultured at a concentration of 1.5 x 106 cells/mL at 
37°C and 5% CO2 for 3 days. A. FACS results for CFSE labeling. B. Cells 
were stained for CD3, CD4, CD8, and CD19 markers and viability was 
tested by 7-AAD. 
Initial Experiment for the Transfer of CFSE-Labeled T Cells  
The goal of this experiment was to determine whether transferred CFSE-labeled 
cells could be located. This experiment represents the first step towards determining if in 
vivo proliferation of transferred CD8+ T cells occurs. As shown in Figure 19, CFSE-
labeled CD8+ T cells could be located in spleens, auxiliary lymph nodes, and inguinal 
lymph nodes in less than 48 hr after CFSE-labeled CD8+ T cells transfer.  
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Figure 19. Initial experiment for in vivo tracking.  
Shown are the results of a setup experiment to detect CFSE- labeled CD8+ 
T cells in spleens (Spl), inguinal lymph nodes (ILN), and auxiliary lymph 
nodes (ALN) in less than 48 hr after their transfer. CD8+ T cells were 
purified from mice receiving no treatments and labeled with CFSE at a 
final concentration of 5µM. CFSE-labeled CD8+ T cells (2 x 106) were 
intravenously transferred to mice and in less than 48 hr, recipient mice 
were euthanized and lymphocytes purified from spleens and inguinal and 
auxiliary lymph nodes, and analyzed for CFSE label by FACS. ALN: 
Lymphocytes purified from auxiliary lymph nodes and labeled with PE-
anti-CD8 monoclonal antibody; Spl: Lymphocytes purified from spleens 
and labeled with PE-anti-CD8 monoclonal antibody; ILN: Lymphocytes 
purified from inguinal lymph nodes; Lymphocytes purified from mice 
receiving CFSE-labeled CD8+ T cells were further labeled with PE-
labeled anti-CD3, -CD4, -CD8, and -CD19 monoclonal antibodies. There 
were not enough cells from inguinal lymph nodes to label for markers. □: 
Lymphocytes purified from spleens; ■: Lymphocytes purified from 
auxiliary lymph nodes. 
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Section 6: Proliferation of CD8+ T cells purified from vaccinated 
mice.  
Thus far it was demonstrated that the combinatory therapy had shown an overall 
benefit over the administration of B16αGal vaccine alone both in the efficacy studies and 
the adoptive transfer experiments. Another mode of IL-15 action that was tested in this 
study was the effects of IL-15 on the proliferation of CD8+ T cells. The question 
addressed was whether or not vaccination with B16IL-15 in combination with B16αGal 
vaccine would improve the maintenance of memory CD8+ T cells by enhancing their 
proliferation. Thus, CD8+ T cells were isolated from vaccinated mice, labeled with CFSE, 
and their proliferation traced in vitro or in vivo. In the in vivo experiment, labeled CD8+ T 
cells were adoptively transferred to syngeneic mice. Recipient mice were then stimulated 
with irradiated B16 melanoma cells (B16N/V) and sacrificed at different time points. 
CFSE-labeled CD8+ T cells were then harvested from recipient mice and CFSE intensity 
was analyzed by FACS. Figure 20 describes the experimental design.  
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Figure 20. The experimental design of in vivo proliferation of CFSE-labeled 
CD8+ T cells.  
CD8+ T cells are purified from vaccinated and non-vaccinated mice, 
labeled with CFSE, and adoptively transferred to syngeneic mice. The 
next day, recipient mice are subcutaneously vaccinated with irradiated 
B16N/V cells to stimulate the transferred CD8+ T cells. Three and six days 
after stimulation mice are sacrificed and spleens are collected and 
processed. Lymphocytes are then analyzed by FACS to determine 
proliferation by CFSE intensity.  
 
The effects of B16IL-15 vaccination on the proliferation of CD8+ T cells 
were first tested in vitro. CD8+ T cells were purified two months after mice were 
vaccinated with B16αGal + B16N/V vaccine or B16αGal + B16IL-15 vaccine. 
CD8+ T cells were stimulated in vitro with irradiated B16N/V cells in the 
presence or absence of IL-2 or with irradiated B16IL-15 cells. All CD8+ T cells 
showed proliferation when data were analyzed by FACS six days after stimulation 
(Figure 21). Under these conditions, it was not possible to detect any effects of the 
in vivo administration of IL-15 on the proliferation of CD8+ T cells. In addition, 
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CD8+ T cells were cultured with 5 x 104 irradiated B16IL-15 cells and on average 
that number of cells was expected to produce 250pg/mL of IL-15 every 48 hr, 
nevertheless the in vitro presence of IL-15 did not add any effects to the 
proliferation of CD8+ T cells compared to other stimulators (Figure 21).  
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Figure 21. In vitro proliferation of stimulated CFSE-labeled CD8+  T cells. 
CD8+ T cells were isolated from mice vaccinated with B16αGal + 
B16N/V (A-E) and mice vaccinated with B16αGal + B16IL-15 (F-J), 
labeled with CFSE and cultured at a concentration of 1.5 x 106 cells/mL in 
24-well plates in a final volume of 2mL RPMI 10. CD8+ T cells were 
either stimulated with irradiated B16N/V cells (C + H), irradiated B16N/V 
cells and IL-2 (D + I), or irradiated B16IL-15 cells (E + J) for six days. A 
+ F represent positive controls (stimulation with CD3/CD28 beads) and B 
+ G represent negative controls (no stimulation).    
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In Vivo Proliferation of Transferred CD8+ T Cells 
The goal of this experiment was to measure the in vivo proliferative potential of 
CD8+ T cells transferred to syngeneic recipient animals. The donors of this experiment 
were mice that survived the subcutaneous challenge with B16N/V melanoma in the 
preventive experiment described above. These animals were used because they survived a 
lethal challenge with B16 melanoma strongly suggesting that they had developed anti-
melanoma T cell reactivity.   
CD8+ T cells were purified from mice vaccinated with B16αGal + B16N/V and 
B16αGal + B16IL-15 vaccines then labeled with CFSE and intravenously transferred to 
recipient mice. The next day, Day 0, mice were stimulated with 1 x 106 irradiated 
B16N/V cells intradermally. On Days 3 and 6, recipient mice were euthanized and 
lymphocytes from non-draining lymph nodes, draining lymph nodes, and spleens were 
purified and analyzed by FACS. Cells were gated according to their CFSE intensity; Gate 
(G) 1, G2, and G3 represent cells with no, one, or two cell divisions in vivo, respectively.  
There was no difference in proliferation between lymphocytes purified from non-draining 
and draining lymph nodes within each group (data not shown). There was no difference 
in the proliferation of splenic CD8+ T cells purified from mice vaccinated with B16αGal 
+ B16N/V and those purified from mice vaccinated with B16αGal + B16IL-15 on Day 3 
(Figure 22A). However, on Day 6, splenic CD8+ T cells purified from mice vaccinated 
with B16αGal + B16IL-15 showed more proliferation than those purified from mice 
vaccinated with B16αGal + B16N/V (Figure 22A). Also on Day 6, CD8+ T cells purified 
from mice vaccinated with B16αGal + B16IL-15 showed more proliferation in the non-
draining and draining lymph nodes of recipient mice than those purified from B16αGal + 
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B16N/V-vaccianated mice (22B).  This result suggests that CD8+ T cells induced in the 
presence of IL-15 demonstrated an increased proliferative potential after in vivo 
stimulation.  
 
Figure 22. In vivo proliferation of transferred CD8+ T cells. 
CD8+ T cells were purified from mice vaccinated with B16αGal + 
B16N/V vaccine and mice vaccinated with B16αGal + B16IL-15 vaccine, 
labeled with CFSE and then intravenously transferred to recipient mice. 
Lymphocytes were purified from recipient mice on Days 3 and 6 after 
stimulation with irradiated B16N/V cells. A. Purified lymphocytes from 
spleens were labeled with anti-CD8 monoclonal Ab. B. Transferred CD8+ 
T cells purified from B16αGal + B16IL-15-vaccinated mice showed a 
higher percentage in Gate 2 than CD8+ T cells purified from B16αGal + 
B16N/V-vaccinated mice in the non-draining and draining lymphocytes. 
Cells were gated according to their CFSE intensity; G1, G2, and G3 
represent cells with no, one, or two cell divisions in vivo, respectively. 
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This experiment was repeated with some modifications. More groups of mice and 
other controls were included in this trial. Mice received three RRBCs immunizations and 
were then vaccinated with 1 x 106 B16N/V cells, 5 x 105 B16αGal + 5 x 105 B16N/V 
cells or 5 x 105 B16αGal + 5 x 105 B16IL-15 cells and from mice that were not 
vaccinated. Fourteen days after the third vaccination, mice were euthanized and CD8+ T 
cells were purified from each group, labeled with CFSE, and adoptively transferred to 
recipient mice. The next day, Day 0, some recipient mice were intradermally stimulated 
with 1 x 106 irradiated B16N/V cells. Mice that did receive labeled CD8+ T cells but were 
not stimulated were used as controls for the FACS analysis on Day 6.  
The only two groups that showed increased proliferation of transferred CD8+ T 
cells in stimulated versus non-stimulated mice are those purified from B16N/V and 
B16αGal + B16N/V treatment groups. See Figure 23A.  
Among groups, transferred CD8+ T cells purified from all treatment groups 
showed enhanced proliferation in spleens of stimulated mice when compared to CD8+ T 
cells purified from non-vaccinated mice (Figure 23B). CD8+ T cells purified from 
B16αGal + B16N/V-vaccinated mice showed more proliferation in spleens of stimulated 
and non-stimulated recipient mice than CD8+ T cells purified from B16N/V-vaccinated 
mice. In addition, CD8+ T cells purified from B16αGal + B16N/V showed more 
proliferation in spleens of stimulated mice than CD8+ T cells purified from B16αGal + 
B16IL-15-vaccinated mice (Figure 23B).   
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Figure 23. In vivo proliferation of CFSE-labeled T cells.  
CD8+ T cells were purified from mice vaccinated with 1 x 106 B16N/V 
cells, 5 x 105 B16αGal + 5 x 105 B16N/V cells or 5 x 105 B16αGal + 5 x 
105 B16IL-15 cells, and from non-vaccinated mice. Purified CD8+ T cells 
were then labeled with CFSE and intravenously transferred to recipient 
mice. The next day, Day 0, recipient mice were either stimulated or not 
with irradiated B16N/V melanoma cells. Lymphocytes were isolated on 
Day 6 and analyzed by FACS. A. Comparison of transferred CFSE-
labeled CD8+ T cells proliferation between stimulated versus not 
stimulated recipient mice (St = Stimulation). B. Comparison of transferred 
CFSE-labeled CD8+ T cells proliferation between the groups of mice from 
which they were purified. Cells were gated according to their CFSE 
intensity. G1, G2, G3, and G4 represent cells with no, one, two or more 
cell divisions in vivo, respectively.    
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DISCUSSION  
An ultimate goal of a vaccine is to elicit a long-term immunological protection 
that can reduce the severity of a disease. Memory T and B cells and long-lived effector B 
cells (plasma cells) constitute the basis of this immunological memory (100) and since 
tumor destruction is mainly mediated by CD8+ T cells, it was rational to hypothesize that 
combining IL-15 with the conventional B16αGal vaccine would increase the efficacy of 
the vaccine by enhancing the maintenance and proliferation of memory CD8+ T cells 
against melanoma. Combination therapy with IL-15 has been widely applied by other 
investigators to treat tumor in murine models (49, 70, 74, 88, 101). 
Thus, the main purpose of this study was to determine whether the incorporation 
of IL-15 with the conventional B16αGal vaccine would increase the proliferation and 
expansion of cytotoxic CD8+ T cells and enlarge the population of long-term memory T 
cells. The results obtained in this study clearly demonstrated a trend supporting the 
hypothesis, indicating that the combination therapy could potentially result in a better 
strategy to treat tumors than a single vaccine regimen.  
In this study several strategies were attempted to demonstrate if the combination 
therapy consisting of B16αGal plus B16IL-15 would result in the improvement of the 
treatment of melanoma tumors. Two tumor models were used. One of the models 
reflected the treatment of a single subcutaneous localized tumor; the other model 
represented the treatment of multiple disseminated metastatic pulmonary tumors. In 
addition, for each of these tumor models two vaccination modalities were performed, the 
treatment of pre-existing tumors in which animals received tumor inoculation and were 
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subsequently vaccinated. The other therapeutic scheme was the preventive vaccination 
model in which animals were vaccinated and subsequently challenged with tumor. 
Results from those experiments demonstrated a statistically significant improvement in 
the treatment and prevention of melanoma when B16αGal plus B16IL-15 combination 
therapy was used compared to the utilization of B16αGal (or B16αGal + B16N/V) 
vaccine alone in three out of 5 experiments (Figures 8, 9, and 10). Moreover, in the pre-
existing pulmonary experiment although there was no significant difference in tumor 
burden between mice receiving the combination therapy and mice receiving B16αGal 
only, the same trend was observed (Figure 7 and Table 6).  All together these data 
provide preliminary support to the hypothesis that combination therapy with IL-15 
increased the efficacy of B16αGal vaccine for the treatment of melanoma  
One of the possible mechanisms by which IL-15 could have potentially increased 
the efficacy of B16αGal vaccine was by the expansion of melanoma specific CD8+ T 
cells and the generation of a larger pool of memory CD8+ T cells that was probably able 
to better clear tumors upon re-encountering melanoma antigens (49, 56, 88). We asked 
the question whether adding B16IL-15 vaccine to the system would indeed increase the 
pool of long term memory CD8+ T cells compared to memory cells induced by the 
conventional B16αGal vaccine. To answer this question CD8+ T cell proliferation studies 
were conducted. CD8+ T cell-donor mice were vaccinated and rested for several months. 
After this period of time, CD8+ T cells were collected, labeled with CFSE, and transferred 
to recipient syngeneic mice that were subsequently vaccinated with irradiated B16 
melanoma cells to stimulate T cell proliferation. Transferred cells were collected and 
proliferation was evaluated by the dilution of CFSE intensity. Results demonstrated that 
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CD8+ T cells isolated more than 3 months after vaccination with B16αGal + B16IL-15 
had indeed shown more proliferation in spleens, non-draining, and draining lymph nodes 
of stimulated recipient mice than CD8+ T cells isolated from mice vaccinated with 
B16αGal + B16N/V cells (Figure 22). Thus, the combination therapy with B16αGal + 
B16IL-15 has demonstrated a slight  overall benefit compared to the administration of 
B16αGal vaccine alone through out this study. Although further investigation is clearly 
needed to confirm these preliminary results, the benefit observed might be due to the 
enhanced maintenance and/or proliferation of CD8+ T cells by IL-15.  
One of the difficulties encountered during the course of this study was the relative 
increase in the efficacy of the B16N/V cell vaccines compared to the B16αGal vaccine.  
Previous publications by our laboratory and others had demonstrated significant 
protection from subcutaneous and pulmonary melanoma of mice vaccinated with αGal-
expressing B16 cells compared to mice vaccinated with B16 cells that do not express the 
αGal epitope (43, 102, 103). The difference in the immunogenicity obtained might be 
explained by the difference in the cell line clones used in the previous publications and 
this study. The B16 cell line clone used in previous publications was the B16BL6 clone, 
whereas the B16F0 clone, purchased from ATTC, was used in this study. It is possible 
that the clone B16BL6 is less immunogenic than the clone B16F0. At this point this 
hypothesis was not systematically addressed and remains speculative.  
In an attempt to solve this problem and be able to detect any differences between 
B16αGal-vaccinated mice and B16N/V-vaccinated mice, the vaccine dose was reduced 
by one-half, to a sub-optimal concentration. Also the vaccination site was changed. We 
tried targeting two lymph node groups rather than one by injecting the mice into the 
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midline rather than into the right flank. In spite of these efforts, only in one out of three 
experiments, was it possible to detect a significant difference between the two treatments 
(Figure 10). In that experiment, mice vaccinated with B16αGal + B16N/V had 
significantly less tumor metastases than mice receiving only B16N/V vaccine cells as 
previously reported. Currently, the utilization of an allogeneic vaccine is (see below) 
addressing this issue better since more consistent results are being demonstrated thus far 
(appendix).  
Another problem encountered in this study was the relatively lower tumor take of 
female mice compared to male mice. As mentioned in the Results section, in two 
experiments (Figures 10 and 16) female mice did not develop tumor metastases as 
expected upon tumor implantation. This incident had been observed by other 
investigators in the laboratory (personal communication). One explanation would be that 
the B16N/V cells used in this study were derived from male mice and males express the 
male-specific minor histocompatibility antigen H-Y. This protein is encoded on the Y 
chromosome and female T cells have been shown to respond to peptides that are derived 
from this protein (104). That resulted in using around half the number of mice originally 
designated for those experiments reducing the power of analysis to detect possible 
smaller differences. 
In this study we evaluated the induction of long-term memory cytotoxic CD8+ T 
cells by the combination therapy by conducting adoptive T cell transfer experiments.  Our 
results do not support that the addition of B16IL-15 vaccine to the conventional B16αGal 
vaccine significantly improved the induction of long-term memory CD8+ T cells. In the 
first transfer experiment, more stringency was added to the system by lowering the 
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vaccine dose and injecting double the tumor cells. A significant difference was only 
detected between mice receiving no CD8+ T cells and mice receiving CD8+ T cells from 
mice vaccinated with B16αGal + B16IL-15. In the second transfer experiment, CD8+ T 
cell purification technique was optimized and thus we obtained highly viable CD8+ T 
cells, but the experiment was prematurely terminated and mice in all treated groups 
contained only very small tumor burdens (Figure 15). The third transfer experiment was 
conducted with no known problems and demonstrated that no significant differences 
existed between the two treatments, CD8+ T cells purified from B16αGal + B16N/V-
vaccinated mice and C8+ T cells purified from B16αGal + B16IL-15-vaccinated mice. 
This result could be explained on the basis that B16αGal vaccine itself is very 
potent and induces a very strong long-lasting cytotoxic-CD8+ T cell activity. It was 
previously demonstrated that B16αGal-vaccinated mice induced cytotoxic CD8+ T cells 
able to treat pre-existing tumors upon transfer to syngeneic mice (43). In those 
experiments, adoptive T cell transfer was performed 2 to 4 weeks after vaccination. It 
was not clear at the initiation of this study for how long this immunologic memory would 
last. Experiments reported here showed that vaccination with B16αGal induced CD8+ T 
cells able to treat most animals upon transfer (Figures 15 and 16.). The cytotoxic activity 
of these CD8+ T cells was found several months (5 and 7 months) after vaccination. The 
addition of B16IL-15 in the described vaccination regimen did not show improvement in 
the activity of transferred cells in the time frame evaluated in this study. Consequently 
under these conditions, combination therapy with B16IL-15 did not induce more effective 
long-term memory pool of CD8+ T cells compared to the conventional B16αGal vaccine.  
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The proliferative potential of purified CD8+ T cells from vaccinated mice was also 
evaluated. CD8+ T cells purified from mice vaccinated with B16αGal and B16IL-15 more 
than three months after vaccination showed more proliferation in vivo by CFSE (Figure 
22) than CD8+ T cells purified from mice vaccinated with B16αGal and B16N/V cells. 
This difference was not observed when CD8+ T cells were isolated two weeks after the 
last vaccination from B16αGal + B16IL-15 vaccinated mice (Figure 23). This is 
consistent with prior data suggesting that IL-15 enhances the maintenance of memory 
CD8+ T either by stimulating their proliferation or sustaining their survival (49, 56, 88).  
Although outside the scope of this study, an additional possible mechanism by 
which IL-15 might increase the efficacy of B16αGal vaccine is through the activation of 
NK cells. IL-15 plays a pivotal role in the proliferation and differentiation of NK cells, 
another set of cytotoxic cells that kill cancer cells (49). In fact, in addition to reduction in 
memory CD8+ T cells, IL-15-/- as well as IL-15Rα-/- mice have significantly reduced NK 
cells, NKT cells, and intestinal intraepithelial lymphocytes (61). Activation and 
proliferation of NK cells might lead to more effective elimination of tumors in vaccinated 
mice. In addition, the role of IL-15 in the inhibition of IL-2-mediated activation induced 
cell death (AICD) is clearly established (79). This process leads to the elimination of self-
reactive T cells. Combining IL-15 with B16αGal vaccine might also result in the 
inhibition of AICD and thus maintaining the number of self-reactive T cells that can act 
against tumor cells. These possible mechanisms were not evaluated in the current study, 
but are currently under investigation by our group. 
Several techniques were optimized and mastered during the course of this study. 
One of the major technical contributions was the purification, CFSE labeling, and in vivo 
 
 75
tracking of CD8+ T cells. The CD8+ T cell purification technique was optimized. 
Additionally, the expected yield of viable CD8+ T cells from mice was possible to 
recover when the technique described in this report was followed. CFSE dye is highly 
toxic to cells and thus it is critical to use the appropriate cell and CFSE concentrations 
with an effective reagent to stop the reaction. The incubation time is another important 
factor in this technique and in our hands the optimum incubation time was five minutes at 
room temperature with continuous mixing. CFSE-labeling of lymphocytes was not 
previously performed in our laboratory. The method described in this report allowed for 
efficient labeling and tracking of lymphocyte proliferation including CD8+ T cells by 
CFSE in vitro and in vivo (Figures 17-19 and 21-23).  
While conducting this project, investigators in the laboratory developed a model 
system that utilizes allogeneic vaccines for the treatment of melanoma, see appendix. 
 Many limitations are overcome by the utilization of allogeneic vaccines. One 
important limitation is the practical difficulty of manufacturing enough autologous cells 
from each individual in case of a syngeneic cancer vaccine, therefore allogeneic vaccines 
are clinically more feasible to prepare. In addition, evidence had shown that antigen-
presenting cells are able to present tumor antigens to naïve T cells through cross-
presentation and possibly inducing a cytotoxic response (105), thereby eliminating the 
need for MHC matching between the vaccine cells and host’s cells. Allogeneic vaccines 
can share tumor associated antigens with autologous tumor. Studies have also shown that 
human melanoma tumor antigens are shared in at least 50% of patients (106). Another 
advantage of using allogeneic vaccines is the possibility of breaking tolerance to 
autologous tumor antigens which most of them are presented by normal cells (107). A 
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wide body of evidence supports the notion that a pre-existing state of tolerance exists 
against a self-antigen present in tumor cells. This tolerance might potentially be broken 
by presenting mutated antigens, antigens in different conformations or antigens with 
different post-translational modifications (108). Recent studies have shown that 
genetically modified and unmodified allogeneic whole cell cancer vaccines are showing 
anti-tumor activity and survival benefits in clinical trials (50, 109, 110). These data also 
encouraged our team to construct an allogeneic vaccine expressing the αGal epitope to 
treat pre-existing tumors in αGT KO mice (appendix). 
Briefly, αGT KO mice (H-2b/b) bearing subcutaneous and pulmonary B16 
melanoma (H-2b/b) showed enhanced survival and reduced pulmonary metastases when 
vaccinated with S91M3αGal (H-2d/d) allogeneic whole cell vaccine compared to mice 
vaccinated with S91M3 vaccine cells and non-vaccinated mice. Vaccination with 
S91M3αGal had also induced cytotoxic CD8+ T cell activity against syngeneic B16 
melanoma tumor which was measured by adoptive transfer to recipient mice bearing 
pulmonary metastases. Furthermore, T cells harvested from mice vaccinated with 
S91M3αGal were cultured with autologous antigen-presenting cells in the presence and 
absence of the melanoma peptide mTRP-2. The recognition of the melanoma peptide by 
those T cells was measured by the expression of TNF-α and CD3 molecule by T cells. In 
this model, the presence of alloantigens did not dominate the immune response and thus 
did not prevent the development of anti-tumor response; instead they contributed to the 
generation of a more effective vaccine compared to the classic autologous B16αGal 
vaccine. Toxicology studies revealed no signs of toxicity or autoimmunity in long-term 
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murine experiments using breast, lung, and melanoma models upon the administration of 
allogeneic vaccines. 
The study shown in the appendix has been submitted for publication. I am one of 
the co-authors of the paper and my responsibility was mainly performing the in vitro T 
cell assays. This included collecting spleens and macrophages from mice and purifying 
splenocytes using the technique described in this report. Spleen mononuclear (Spm) cells 
were then cultured with the freshly isolated peritoneal macrophages to determine 
intracellular cytokines in presence or absence of peptides. The peptides used were the 
melanoma peptide mTRP-2 and non-melanoma peptide OVA. Intracellular TNF-α was 
detected using a mouse detection kit (BD Pharmingen) following manufacturer’s 
instructions. Vaccination with the allogeneic S91M3αGal vaccine had induced T cells 
that recognized the melanoma peptide mTRP-2 presented in the context of autologous 
MHC. This expression was not observed when T cells were pulsed with OVA nor by T 
cells purified from non-vaccinated mice. In addition, the responsibilities included testing 
culture supernatants for IFN-γ production by ELISA (data not shown). Finally, I 
participated in reviewing and editing the paper before submission.  
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CONCLUSION 
The combination of IL-15 with B16αGal vaccine appeared to improve the 
efficacy of the B16αGal vaccine in preventing and treating melanoma. This was 
demonstrated in four out five in vivo experiments using αGT KO mice. In three of these 
experiments, the efficacy of the B16αGal vaccine was significantly enhanced when 
combined with B16IL-15 vaccine cells. This significance was achieved in the therapeutic 
subcutaneous model as well as in the preventive subcutaneous model.  
CFSE labeling experiments demonstrated that CD8+ T cells induced more than 3 
months after vaccination with B16αGal plus B16IL-15 proliferated more than CD8+ T 
cells induced after vaccination with B16αGal plus B16N/V. These preliminary results are 
consistent with prior data suggesting that IL-15 enhances the proliferation of long term 
memory CD8+ T cells.  
Unfortunately, it was not possible to reproduce some of the results shown in this 
report. In other experiments, for example the adoptive transfer experiments, we were not 
able to show significant differences between the administration of B16αGal vaccine and 
the combination therapy. Further characterization of long-term memory CD8+ T cells 
using different parameters than those used in this project might highlight more 
differences in the quality and quantity of these cells induced by single versus 
combinatory treatment. Additionally, increasing the number of mice per group to increase 
the power of analysis to detect small differences and/or changing to the allogeneic model 
might confirm possible differences between the combination therapy and B16αGal 
vaccine therapy.  
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  To conclude, this study showed a trend suggesting that the combination of B16IL-
15 with the B16αGal vaccine might result in an improved therapeutic approach to treat 
melanoma in murine models.  
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Abstract  
Due to the absence of αGal epitopes in human cells and constant stimulation of 
the immune system by the symbiotic bacterial flora, humans develop high titers of natural 
antibodies against these epitopes. It has been demonstrated that syngeneic whole cell 
vaccines modified to express αGal epitopes could be used to generate a potent anti-cancer 
vaccine. In this study we tested whether allogeneic whole cell cancer vaccines modified 
to express αGal epitopes would be effective for the treatment of murine melanoma. α 
(1,3)Galactosyltransferase (αGT) knockout mice (H-2b/b) with pre-existing subcutaneous 
and pulmonary tumors (αGal(-) B16, H-2b/b) received therapeutic vaccinations with 
S91M3αGal(+) (H-2d/d) whole cell allogeneic vaccines . These mice had better survival 
and reduced pulmonary metastasis burden compared to control mice treated with S91M3 
vaccine cells.  Vaccination with S91M3αGalinduced cytotoxic CD8+ T cells recognizing 
the syngeneic αGal(-) B16 tumors measured by adoptive transfer to recipients bearing 
pulmonary metastases. The presence of allo-antigens does not dominate the induction of 
immunity to “cryptic” tumor antigens and helped in the generation of a more efficient 
vaccine to treat pre-existing tumors when compared to classic autologous vaccines. 
Vaccination with allogeneic αGal(+) vaccines did not induce signs of toxicity including 
changes in weight, hematology, chemistry and histopathology of major perfused organs 
or autoimmunity in long-term murine models for breast, lung and melanoma. This study 
establishes the safety and efficacy data of allogeneic αGal(+) whole cell vaccines and 
constituted the basis for the initiation of human clinical trials to treat human 
malignancies.  
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Introduction 
The human immune system is continuously stimulated by intestinal and 
pulmonary bacterial flora to produce natural antibodies that recognize αGal epitopes  (1) . 
These anti-αGalantibodies, which can reach up to 1% of circulating IgG, are capable of 
mediating a ‘‘hyperacute rejection’’ of tissues and cells expressing αGal epitopes. This 
phenomenon is mediated by the binding of anti-αGalantibodies to αGal epitopes and 
complement activation through the classic pathway (2). In addition, non-complement 
fixing natural anti-αGalantibody induces antibody-dependent cell cytotoxicity (ADCC) 
that initiates tissue damage (3, 4). We have exploited this immune mechanism to create a 
whole cell cancer vaccine to treat melanoma tumors. Previous studies using the α(1,3)-
galactosyltransferase (αGT) knockout mouse model, demonstrated that syngeneic B16 
melanoma vaccines genetically engineered to express αGal epitopes (B16αGal) 
effectively treated pre-existing subcutaneous and pulmonary αGal(-)  melanoma (B16F0) 
tumors (5, 6).  
In order to translate this type of vaccine to the clinic, the practical difficulties of 
raising enough autologous cells from each individual as well as of developing clinically 
acceptable standard procedures for vaccine manufacturing have to be overcome. The use 
of allogeneic αGal(+) vaccines would solve these limitations and making it clinically and 
industrially feasible to prepare a single vaccine containing a broad set of representative 
tumor associated antigens (TAA).  
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There is a considerable body of evidence showing that through the phenomenon 
of cross-presentation, tumor antigens from vaccine tumor cells are presented to naïve T 
cells by the host's antigen presenting cells, thereby eliminating the need for MHC 
matching between the vaccine and host's cells (7)  
However, the approach of using allogeneic vaccines requires that tumor cells used 
as vaccines share some cross-reactive TAA with the autologous tumor. Most tumor cells 
have unique expression profiles of TAA, but in many cases these TAA are unknown or 
very difficult to identify or isolate from individual tumors. Studies show that human 
melanoma tumor antigens are shared in at least 50% of patients (8). Therefore, the use of 
whole cell vaccines alleviates this difficulty, as it provides a whole repertoire of TAA 
without the need to isolate or characterize those antigens.  
Additionally, most tumors escape immune surveillance because the immune 
system has been tolerized to autologous TAA. A wide body of evidence supports the 
notion that a pre-existing state of tolerance against a self-antigen present in tumor cells 
can be broken by presentation of mutated antigens, antigens in different conformations or 
with different post-translational modifications (9). Allogeneic whole cell vaccines 
comprised of TAA showing allelic variation with the target tumor may be useful in 
breaking tolerance to those autologous TAA.   
However, the induction of an effective anti-tumor immune response is anticipated 
to require the activation of autoreactive T cells that recognize autologous antigens present 
in tumors and normal tissues. Since most tumors share antigens with normal tissues, it is 
expected that an effective vaccination therapy may have a secondary effect on the 
induction of autoimmune reactions against normal tissues. This has been clearly 
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demonstrated in melanoma therapies in human clinical trials. (10, 11) and in mouse 
models (12-14). On the other hand, other animal studies have shown that vaccination 
protocols can generate substantial antitumor immunity with little, or no, autoimmunity 
(13, 15-18).   
Genetically modified or unmodified allogeneic whole cell cancer vaccines are 
showing anti-tumor activity and survival benefits in clinical trials, thereby validating the 
hypothesis that immune rejection of laboratory produced human cancer cell lines can 
induce destruction of patient's malignancies (19-21).   
In this study we determined whether allogeneic vaccines expressing αGal epitopes 
are as effective in the treatment of pre-existing tumors as previously described αGal(+) 
syngeneic vaccines (5, 6). Also, we assessed whether the vaccination with allogeneic 
vaccines expressing αGal epitopes induced signs of autoimmunity or other type of 
toxicity in murine models for vaccines to treat lungs, breast and melanoma cancers.  
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Materials and Methods 
α(1,3)Galactosyltransferase (αGT) knockout (KO) animals 
Females and males 8 to 14 weeks old αGT KO mice were used in this study. 
Several founders of the original colony αGT KO mice were purchased from Dr. J.B. 
Lowe (University of Michigan) (22). The original αGT KO mouse expressed both alleles 
H-2b and H-2d haplotypes. These animals were generated by crossing C57BL/6 x DBA/2J 
x 129sv mice (H-2b x H-2d). In an effort to obtain homozygous colonies, by breeding and 
selection, we generated two αGT KO mouse colonies homozygous for both H-2b/b and H-
2d/d haplotypes. Animals used in this study express H-2Kb and H-2Db haplotypes and they 
do not express H-2Dd or H-2Kd  (6).  
Mice were immunized intraperitoneally (i.p.) with 1 x 108 rabbit red blood cells 
(RRBC) twice, two or three weeks apart to increase the anti-αGalantibody titers (23). The 
presence of elevated titers of anti-αGalAb was confirmed one week after the last RRBC 
immunization.  
 
Cell lines and vaccine preparation  
The following murine melanoma cell lines were used in this study: B16F0 
(originated in C57Bl/6 mice, H-2b/b) and S91M3 (ATCC number CCL-53.1, H-2d/d). 
These cell lines do not express αGT gene due to down regulation of the αGT gene 
expression (24-26).  
Melanoma cells were transduced with a lentiviral vector expressing αGT gene to 
produce cell lines expressing αGal epitopes (B16αGaland S91M3αGal) as previously 
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described (27). Briefly, the αGT murine gene was cloned into a self inactivating HIV-
based vector under the control of the human PGK promoter (pHSPA). Viral vector 
supernatants were collected two days after transfection of 293T cells and used to stably 
transduce melanoma cells. The efficiency of the transduction and expression of αGal 
epitopes in cell lines used in this study were determined by IB4 lectin staining (6). Also 
the Lewis Lung Carcinoma (LLC ATTC number CRL-1642) and EMT-6 cells (ATTC 
number CRL-2755) were used as positive controls for staining. These cell lines naturally 
express the αGT gene (Supplementary 1). For vaccine preparation, cells were expanded 
in complete Dulbecco’s Modified Eagle medium (DMEM) media, harvested and 
irradiated with 200 Gy. Irradiated cells (vaccines) were stored frozen in appropriated 
aliquots. At the moment of inoculation, vaccine cells were thawed, washed and 
resuspended in sterile saline solution at the appropriate concentration for injection.  
 
Detection of αGalepitopes by Fluorescence Activated Cell Sorting (FACS) 
To detect the expression of αGal epitopes, cells were stained as previously 
described (5, 6, 23). Briefly, 5 µl of the fluorescein isothiocyanate (FITC)-labeled 
Griffonia simplicifolia isolectin B4 (IB4, Molecular Probes), was added to one million 
cells in Hybridoma Serum Free media (Invitrogen-Life Technologies), Cells were 
incubated for 30 minutes, washed and analyzed by FACS. This lectin has previously been 
shown to bind specifically to αGal epitopes (28).  
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Animal treatments for efficacy studies  
S91M3 melanoma cells (H-2d/d) were transduced with pHSPA vector to produce 
S91M3αGalcells. The melanoma cell line B16F0 (H-2b/b) was used to establish 
pulmonary tumors in αGT KO mouse (H-2b/b) as previously described (6). Mice received 
two or three RRBC injections to increase anti-αGalAb. Subsequently, they were 
challenged intravenously (i.v) or subcutaneously (s.c.) with 5x104 to 105 B16F0 viable 
cells. At 4 to 5 days after tumor challenge, animals received either no treatment or were 
vaccinated subcutaneously with three weekly doses of 1x106 S91M3αGalor control 
vaccines, S91M3 (αGal(-) vaccine).  
Mice that had pulmonary metastases were humanely euthanized 28 days after 
receiving B16F0 cells. Pulmonary metastases were enumerated in a blinded manner or 
tumor loads were determined by weighing lungs obtained in block. Spleens were also 
collected for additional analysis. Mice that had pre-existing subcutaneous tumors were 
euthanized when their tumors reached a volume higher than 1000 mm3. To ensure 
minimal distress, pain or discomfort, all animal procedures were performed according to 
the Institutional Animal Care and Use Committee (IACUC) approved protocols.  
 
In vitro T cell assays 
Mice were pre-immunized with RRBC and subsequently vaccinated with three 
s.c. injections of irradiated S91M3αGal cells one week apart. Spleen mononuclear (Spm) 
cells were harvested and cultured with freshly isolated peritoneal macrophages to 
determine intracellular cytokines in presence or absence of peptides. Intracellular TNF-α 
 
 97
was detected using a mouse detection kit (BD Pharmingen) following manufacturer’s 
instructions. Briefly, 1 x 105 antigen-presenting cells (APCs) /mL were pulsed with 
mTRP-2 180-188 (SVYDFFVWL) or OVA 257-264 (SIINFEKL) peptides for two hours. 
Effector Spm cells were added and incubated for 6 hours in presence of Golghi Plug™ 
(BD, Pharmingen). Cells were harvested and stained for intracellular TNF-α and CD3 
expression. Acquisition was performed using Coulter flow cytometer Epics Ultra™ 
(Miami, Florida) using Expo32 Software.  
 
Adoptive transfer of CD8+ T cells with anti-tumor activity  
αGT KO mice were intravenously injected with 3 x 105 B16F0 viable cells and 
randomized 8 days before receiving adoptive T cell transfer therapy. Donor αGT KO 
mice were first primed with two RRBC immunizations and then received three weekly 
vaccinations with 1 x 106 allogeneic melanoma vaccines expressing or not αGal epitopes 
(S91M3αGalor S91M3 vaccine cells). Two weeks after the last vaccination splenocytes 
were harvested and CD8+ T cells were purified by magnetic sorting as previously 
described (5). Recipient mice received 2 x 105 purified CD8+ T cells administered 
intravenously. Pulmonary melanoma burden was determined 28 days after tumor 
inoculation.  
 
 
 98
Dominance of the immune response.  
We used the pre-existing pulmonary melanoma metastasis model to determine if 
the allogeneic property of the vaccines used in this model induces an allogeneic response 
that dominates over the induction of anti-tumor immunity.  
αGT KO mice were immunized as before with RRBC. One week after the last 
RRBC injection they were injected intravenously with 5x104 viable B16 melanoma cells. 
On days 4, 11 and 18 after tumor inoculation mice received a total of one million vaccine 
cells. Animals were divided into the following groups: Group 1 received the syngeneic 
B16αGalvaccine alone (106 cells); Group 2 received a combination of the syngeneic 
B16αGalvaccine (5 x 105 cells) with the allogeneic S91M3αGalmelanoma vaccine (5 x 
105 cells);  Group 3 received an αGal(+) non-melanoma allogeneic whole cell vaccine 
(EMT-6 (H2-Kd/d and H2-Dd/d) breast cell line, 5 x 105 cells); Group 4 received a mixture 
of the syngeneic B16αGalvaccine (5 x 105 cells) and the EMT6 non-melanoma vaccine (5 
x 105 cells);  and Group 5 received no vaccination (controls).  
The breast cell line EMT-6 was selected because it was shown before to share 
several cancer-testis antigens with melanoma (29, 30). As before, four weeks after tumor 
inoculation animals were euthanized and lungs metastases quantified by counting tumors 
in the lungs and by measuring lungs weights.  
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Kinetics of anti-αGalantibody titers after administration of allogeneic 
vaccines  
Three groups of αGT KO mice (H-2d/d haplotype) were used to evaluate the anti-
αGalantibody response to RRBC or RRBC plus allogeneic αGal(+) cell vaccination. 
Group 1: were naïve αGT KO mice that did not receive any immunizations. Group 2: 
were αGT KO mice that received three intraperitoneal doses of 108 RRBC immunizations 
at days 1, 14 and 28.  Group 3 were αGT  KO mice that received the same three doses of 
RRBC at days 1, 14 and 28 plus 6 subcutaneous doses of 106 irradiated αGal(+) LLC cells 
(H-2b/b) at days 35, 42, 49, 56, 63 and 70. Blood was collected from all animals at days 
32 (4 days after the last RRBC immunization), 46 (4 days after the second LLC 
immunization) and 75 (5 days after the last LLC vaccination. The anti-αGalAb titers were 
determined by ELISA as previously described. To quantify the amount of anti-αGalAb 
(IgG or IgM) an affinity purified chicken anti-αGalAb standard was used. Results are 
expressed as Units of anti-αGalAb, each unit corresponding to 1 g/mL of anti-αGalAb 
standard.  
 
Toxicology studies in mouse models  
 
Allogeneic lung cancer model 
LLC cells are generated from wild type C576Bl mice (H-2b/b haplotype) and 
naturally express the αGT gene (6). These cells were used for toxicology studies as a 
prototype cell for vaccination of H-2d/d αGT KO mice with allogeneic cells. Females and 
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males were injected intraperitoneally with RRBC to increase the anti-αGalAb titers. One 
week after the last RRBC injection, they received 6 weekly doses of 106 irradiated LLC 
vaccine cells, s.c. Mice were weighed weekly during the course of LLC vaccination and 
subsequently weighed bi-weekly. Complete blood counts, differential counts and 
histopathology data were collected from all groups 24 hours , 2 months and 6 months 
after the last LLC vaccine administration.  
 
Allogeneic breast cancer vaccine model  
The EMT-6 breast tumor cell line was originated in Balb/c mice (H-2d/d 
haplotype) and naturally expresses the murine αGT gene. These cells were used for 
toxicology studies for vaccination of H-2b/b αGT KO mice with allogeneic cells. Female 
αGT KO mice (H-2b/b haplotype) were vaccinated intraperitoneally twice two weeks 
apart with RRBC to increase titers of anti-αGalantibodies. One week after the last RRBC 
immunization, mice received the first dose of 5 x 105 irradiated EMT-6 (αGal(+)  cells. 
This dose was repeated 3 times, one week apart. Animals received a total of four 
subcutaneous EMT-6 vaccine doses. One week after the last EMT-6 vaccination, some 
mice were euthanized and tissues and blood samples were obtained for hematology and 
serum chemistry (one week data). Mice were monitored for a total of six months after the 
study was completed. Tissues and blood samples were analyzed six months after last 
EMT-6 vaccine (six months data). Also, body weight was measured weekly in the first 
month of the study and subsequently it was measured bi-weekly until the end-of the 
study. Necropsy and gross pathology was performed for all animals when they were 
euthanized. Organs in which histopathology was performed included liver, spleen, 
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kidneys, mammary glands, lungs and skin.  
 
Allogeneic Melanoma vaccine model 
αGT KO mice (H-2d/d) received two RRBC immunizations as described above. 
Subsequently they received 6 weekly doses of 106 B16αGal(H-2b/b) vaccines 
administered subcutaneously. These mice were weighed bi-weekly during 6 months. 
Blood samples and major perfused organs were obtained 2 weeks and 6 months after the 
last melanoma vaccine for analysis.  
 
Statistical analysis  
GraphPad Prism software was used for statistical analysis. Kaplan-Meier survival 
analysis and log-rank tests were used for curve comparisons. One-way ANOVA and or 
Student t test were used when appropriate.  
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Results  
Treatment of pre-existing pulmonary melanoma metastasis with allogeneic 
melanoma vaccines 
We developed a model of allogeneic vaccines to treat pre-existing metastatic 
melanoma using αGT KO H-2b/b mice challenged with B16F0 (H-2b/b) melanoma tumor 
cells and vaccinated with S91M3αGal(H-2d/d) allogeneic melanoma vaccines. Allogeneic 
melanoma vaccines expressing αGal epitopes significantly reduced the number of 
pulmonary melanoma metastases (Figure 1, A). Moreover 3 out of 12 animals receiving 
S91M3αGalwere tumor free (arrows in Supplementary Figure 1). On striking contrast 
vaccination with allogeneic vaccines in the absence of αGal epitopes (S91M3 vaccines) 
had no significant impact on the number of B16F0 tumors developed compared to 
animals receiving no treatment. Moreover, none of the animals in both control groups 
were tumor free (Supplementary Figure 1).  
To confirm the data, this experiment was repeated increasing the number of 
animals in each group. Results confirmed that vaccination with S91M3αGalallogeneic 
melanoma vaccines significantly reduced the number of B16F0 metastases in lungs of 
this group of mice compared to animals receiving either no treatment or  αGal(-) S91M3 
vaccine. (Figure 1, B C D and E). Moreover, several animals in control groups had 
tumors localized at distal sites (peritoneal cavity and liver metastasis, Red Arrows Figure 
1). None of the animals receiving S91M3αGalvaccines had disseminated disease (Figure 
1 E). It is worth highlighting that animals receiving S91M3αGalvaccines had 
significantly smaller tumors compared to control animals (Figure 1 E).   
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Treatment of pre-existing subcutaneous melanoma tumors 
We tested whether immunization with allogeneic S91M3αGalvaccines could 
prolong the survival of mice bearing pre-existing subcutaneous melanoma tumors 
compared to vaccination with allogeneic cells lacking αGal epitopes (Figure 2). αGT KO 
animals were primed with three RRBC immunizations to raise the titers of anti-
αGalantibodies and subsequently inoculated with 105 B16F0 tumor cells. Four days later 
they received the first dose of either saline solution, 106 S91M3 or S91M3αGalvaccine 
cells. They received two more doses of each treatment at weekly intervals. The mean 
survival time for the non-vaccinated control animals was only 19 days, whereas for 
animals receiving S91M3 or S91M3αGalvaccines was 33 and 76 days, respectively. 
Vaccination with allogeneic S91M3 or S91M3αGalcells produced a significant increase 
in survival compared to untreated controls (p=0.01 and p=0.0001, respectively). The 
presence of αGal epitopes on the allogeneic S91M3αGalvaccine cells improved the 
median survival (76 vs. 33 days) and long term survival proportion (45% vs. 15%) 
compared to immunization with S91M3 lacking αGal epitopes (p=0.044). This 
experiment was repeated and similar results were found (not shown). These experiments 
demonstrate that vaccination of an animal having elevated titers of anti-αGalantibodies 
with αGal(+) allogeneic tumor vaccines can effectively treat pre-existing autologous 
melanoma tumors improving long-term survival over allogeneic vaccination with αGal(-) 
cells.  
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Adoptive transfer of melanoma-specific CD8+ T cells induced by 
allogeneic vaccines expressing αGal epitopes 
We determined whether the presentation of αGal epitopes on whole cell 
allogeneic cancer vaccines induces T cells that recognize syngeneic melanoma cells 
lacking the expression of αGal epitopes. To evaluate this, we performed adoptive T-cell 
transfer therapy from αGT KO mice that were vaccinated with S91M3 or S91M3αGalinto 
recipients bearing syngeneic B16F0 intrapulmonary metastases (Figure 3 A and B). A 
significant reduction in pulmonary melanoma metastases was observed in mice receiving 
purified CD8+ T cells from mice vaccinated with S91M3αGalcompared to mice that 
received no treatment (p<0.0001), CD8+ T cells from non-vaccinated animals (p=0.013) 
and CD8+ T cells from mice vaccinated with S91M3 cells lacking αGal epitopes 
(p=0.04). 
This result indicates that the vaccination with S91M3αGalcells induced cytotoxic 
CD8+ T cells that recognize autologous tumor antigens. When transferred to animals 
with pre-existing tumors these CD8+ T cells significantly reduced the lung melanoma 
burden when compared to un-treated and control mice.   
To further demonstrate that the vaccination with αGal-expressing vaccines 
induces T cells recognizing autologous tumors, we cultured T cells from vaccinated 
animals with autologous APCs in the presence or absence of melanoma peptide. As 
demonstrated in Figure 3C, vaccination with allogeneic S91M3αGal induced T cells 
recognizing melanoma peptide mTRP-2 presented in the context of autologous MHC. 
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These results confirmed the induction of anti-tumor immunity directed to autologous 
tumor antigens.  
 
Dominance of the immune response 
Ideally, an antigenically complex vaccine is expected to elicit a broad range of 
specific T-cell responses to the many antigens present in the vaccine composition. 
However, even though the vaccine contains a plurality of potential epitopes, the T-cell 
response tends to become focused on just few epitopes. This economizing by the immune 
system is referred to as immunodominance and has hindered approaches using 
multivalent vaccines that deliver multiple T-cell epitopes simultaneously (31). In 
addition, the response to allogeneic major histocompatibility complex molecules is one of 
the most potent types of T cell mediated reactions that prevents allo-transplantation 
among non–histocompatible individuals.  
In the case of whole cell cancer vaccines that express different HLA antigens than 
the recipient subjects, one could question the ability of such vaccine to induce anti-tumor 
immunity because the allogeneic response could be dominant over the T cell response 
elicited toward the multiplicity of different tumor antigens.  
On the other hand, the non-specific activation of T cells due to the presence of 
allogeneic MHC antigens could improve the reactivity against “cryptic” tumor antigens.  
We asked the question of whether the presence of allogeneic MHC antigens 
would affect the anti-tumor immune reaction induced by allogeneic vaccines in 
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comparison to the anti-tumor immune response previously observed towards syngeneic 
αGal(+) whole cell vaccines (5).  
We can envision three possible scenarios. First, T cells recognizing MHC 
alloantigens will dominate the immune response. This will prevent the development of 
tumor specific T cells since most tumor antigens are considered “cryptic” or non-
immunodominant. Second, allo-reactivity and the induction of an efficient anti-tumor 
immunity could occur simultaneously and independently. Third, the immune response 
towards allogeneic MHC molecules could have an adjuvant effect that increases the T 
cell response towards tumor antigens. An allogeneic reaction towards MHC molecules 
could trigger the expansion of allo-reactive T cells and inflammatory effector 
mechanisms similar to the reactions occurring during allograft rejection. This will 
culminate in the activation of autologous APCs, the presentation of tumor antigens to T 
cells and the organization of a more effective anti-tumor immune response. These 
possible outcomes were tested by treatment of mice with pre-existing pulmonary 
melanoma tumors with different vaccine combinations (Figure 4).   
As previously shown, syngeneic αGal(+) vaccine cells effectively reduced the 
lungs melanoma metastasis burden (B16αGalalone, G1 vs. No treatment G5) (5). The 
combination of αGal(+) syngeneic and allogeneic melanoma vaccines further improved 
the efficacy of the treatment compared to non treated controls (G2 vs. G5, p<0.0001) and 
compared to vaccination with the syngeneic vaccine alone (G1 vs G2, p=0.0167). 
Interestingly, mice vaccinated with αGal(+) allogeneic breast cancer vaccine alone or in 
combination with syngeneic melanoma vaccine had reduced melanoma burden compared 
to animals receiving no treatment (G3 vs. G5, p=0.0053 and G4 vs. G5, p<0.0001). The 
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reduction in the lung melanoma metastasis burden in G3 and G4 might be explained by 
the presence of shared cancer-testis antigens in these two types of cell lines (29, 30, 32).  
This experiment shows that the presence of allo-antigens in whole-cell vaccines 
expressing αGal epitopes does not dominate the immune response and thus preventing 
the development of an antitumor T cell response. Moreover, the results suggest that the 
presence of allogeneic MHC molecules provides an adjuvant effect helping the 
organization of a more efficient therapeutic anti-tumor immune response.  
 
Kinetics of anti-αGalantibodies titers after administration allogeneic cell 
vaccines  
A question that was raised while using those animal models is whether the anti-
αGalAb level induced by RRBC immunization remains high or is further elevated during 
the course of subcutaneous immunizations. This is an essential requirement for the 
effective induction of anti-tumor immunity using αGal(+) vaccines. To answer the 
question we tested the levels of anti-αGalAb (IgG and IgM) during a period of 46 days 
after the last RRBC immunization. Additionally, we determined whether the 
subcutaneous administration of six doses of allogeneic cells expressing αGal epitopes 
affected the kinetics of anti-αGalAb (Figure 5). As described previously, naïve αGT KO 
mice produce low to undetectable titers of anti-αGalAb. All mice injected with RRBC 
produced more the anti-αGalAb compared to naïve controls. In mice receiving only 
RRBC the concentration of anti-αGalAb IgG slowly decreased over time in the 46 days 
study (Figure 5). The anti-αGal Ab concentration was reduced in mice that received only 
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RRBC immunizations during the time course of this experiment. On the contrary, mice 
receiving LLC vaccination during a period of 46 days, showed significantly higher anti-
αGalAb IgG concentration after administration of subsequent subcutaneous doses of 
allogeneic vaccines. On the other hand, the anti-αGalIgM titers slowly decreased after the 
last RRBC immunization in the presence and absence of vaccination with αGal(+) 
allogeneic cells. With this study we conclude that during the period in which allogeneic 
vaccines are administered the anti-αGalAb level (IgG and IgM) remains high and the 
anti-αGalAb IgG titers are further increased.  
 
Long-term toxicology studies in murine model for lung, breast and 
melanoma cancers.  
Growth patterns of animals receiving allogeneic vaccines  
We conducted three studies in order to evaluate long-term effects on animals receiving 
αGal(+) allogeneic vaccines. Mice were either untreated (naïve) or received RRBC 
immunizations. Test groups received also LLC vaccines (model for αGal(+) lung cancer 
allogeneic vaccines), EMT-6 vaccines (model for αGal(+)  breast cancer allogeneic 
vaccines) or B16αGalvaccines (model for αGal(+) melanoma vaccines). Animals were 
monitored for six months measuring body weight as an indication of a general animal 
condition (Supplementary 2).   
For all three models we conclude that the administration of allogeneic vaccines has no 
impact on the growth patterns of immunized animals.   
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Hematology data of animals receiving allogeneic vaccines  
Blood samples from animals enrolled in these studies were obtained at different time 
points after the administration of allogeneic vaccines. Complete blood counts and 
differential counts were determined for the allogeneic lung, breast and melanoma vaccine 
models. No significant differences were found in groups receiving no treatment, RRBC 
immunizations only or RRBC immunizations plus allogeneic vaccines expressing αGal(+) 
epitopes ( Supplementary 3).  
 
Histopathology data of animals receiving allogeneic vaccines  
Tissues were collected from mice at different points after receiving allogeneic vaccines 
(Supplementary 4). 
Histological evaluation of heart, liver, kidneys, spleen, breast and skin for each mouse in 
all groups resulted in the majority of samples being within normal histological limits. The 
microscopic lesions observed in these studies are not uncommon in conventionally-reared 
mice and were not considered significant. 
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Discussion  
In the present study we found that the administration of allogeneic αGal-
expressing melanoma vaccine induces reduction in the lung melanoma metastasis burden 
in mice with pre-existing lungs tumors and prolongation of mean survival time in mice 
with pre-existing subcutaneous tumors. The efficacy of the vaccine is mediated by CD8+ 
T cells as demonstrated by adoptive T cell transfer studies.  Additionally, we 
demonstrated that the presence of allogeneic MHC molecules in the vaccine cells does 
not dominate the induction of an effective antitumor response, but instead it seems to 
provide an enhancing antitumor effect. Finally, the results show that an effective 
antitumor response in this therapeutic setting does not seem to be associated with 
concomitant autoimmunity.  
In our experiments, a significant extension in the median survival time or 
reduction in tumor burden can be obtained by vaccination using whole cell allogeneic 
cells.  However, a significant increase in survival time and reduction in tumor burden can 
be further obtained by modifying allogeneic vaccine cells with αGal epitopes.  
Our data showed that αGal(+) allogeneic melanoma cell vaccine can prolong the 
survival and achieve a complete response in 45% of animals bearing early stage pre-
established (i.e 4-5 days) B16F0 tumors. 
The mechanism proposed for the enhanced efficacy of allogeneic 
S91M3αGalvaccine cells compared to S91M3 is based on the interaction of this vaccine 
with pre-existing anti-αGalantibodies. Opsonization of αGal(+) vaccine cells by anti-
αGalantibodies would promote their phagocytosis by macrophages and other antigen 
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presenting cells. Additionally, opsonization would favor the uptake of immunocomplexes 
through Fcγ receptors, which promotes the efficient uptake of antigen, cross-presentation 
in both MHC Class I and II, and APC activation and maturation of dendritic cells. Thus, 
antigen presentation by endogenous APCs and cross presentation make MHC matching 
between the vaccine tumor cells and the vaccine recipient unnecessary.  
Although we do not know the possible cross-reactive antigen(s) being targeted by 
the immune response, adoptive T cell transfer and in vitro T cell analysis showed that the 
allogeneic vaccine generated CTLs specific for B16F0 and T cells recognizing mTRP-2 
peptide. The present allogeneic vaccine model has clinical significance as all the human 
melanoma antigens identified so far are shared by at least 50% of patients. Indeed, other 
tumors like renal carcinoma appear to follow the same pattern and 35% of lung 
carcinomas expresses the antigen MAGE 28 (33).  
In the present study we observed no evidence of toxicity or autoimmune effects. 
We evaluated several parameters in three animal models for allogeneic vaccines 
expressing αGal. We conclude that the administration of allogeneic vaccine has no 
impact on the growth patterns of animals when compared to animals receiving RRBC 
only and animals receiving no treatment. We also demonstrated that no significant 
abnormalities were observed in major perfused organs analyzed by macroscopic necropsy 
and histopathology. Mice receiving no vaccine (RRBC only), EMT-6, LLC or 
B16αGalvaccines and non-manipulated aged and sex-matched naïve mice had similar 
lesions in lungs and other organs analyzed. No significant differences were observed in 
the hematology results including the hemogram, differential blood counts and blood 
chemistry results in any of the groups in all of the experiments performed. . 
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Consequently, we conclude that the administration of allogeneic vaccines does not induce 
any signs of autoimmunity or other type of toxicity. These results provide convincing 
evidence for the safety of αGal(+) allogeneic vaccines for future clinical trials.  
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Figure Legends 
Figure 1: Treatment of pre-existing pulmonary melanoma tumors.  
Mice were immunized i.p. with RRBC to increase the anti-αGalAb titers. One week after 
the last RRBC immunization, pulmonary metastases were established by i.v. injection of 
8 x 104 viable B16F0 cells. Mice received either 1x106 S91M3 or S91M3αGalvaccine 
cells or no treatment on days 4, 12 and 19 after tumor inoculation. On day 28 after tumor 
inoculation, mice were humanely euthanized and lungs were collected. Pulmonary tumors 
were enumerated in a blinded manner (A). Results from two experiments are shown and 
express the mean of tumors burden in each group and errors are the SEM (A and B). The 
number of animals in each group is indicated. Lungs pictures from animals in panel B are 
shown for non-vaccinated animals (C) or from animals vaccinated with S91M3 (D) or 
S91M3αGal(E). Arrows show tumors localized in distal sites (peritoneal cavity and liver 
metastasis) in control groups. . 
Figure 2. Treatment of pre-existing subcutaneous melanoma tumors.  
Mice were vaccinated with RRBC as before and then challenged subcutaneously with 105 
B16F0. On days 5, 12 and 19 they received 1x106 S91M3 or S91M3αGalvaccine cells. 
Survival analysis was performed using log-rank test. The difference in the mean survival 
using log-rank test is indicated   
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Figure 3 Adoptive T cell transfer of melanoma specific T cells induced by 
allogeneic vaccines expressing αGal.  
A. Donor mice were vaccinated with RRBC as explained before. One week after the last 
RRBC immunization, mice received three weekly doses of whole cell vaccines (S91M3 
or S91M3αGal). Two weeks after the last vaccination mice were humanely euthanized 
and spleens were collected. CD8+ T cells were purified by magnetic cell sorting. 
Recipient mice were injected i.v. with 3 x 105 B16F0 viable cells. Eight days after tumor 
challenge they were randomized into four different groups and subjected to the following 
treatments: Group 1 received no T cells (T1); group 2 were inoculated intravenously with 
2 x 105 purified CD8+T cells from non-vaccinated animals (T2); group 3 received CD8+ 
T cells from mice vaccinated with S91M3 cells (T3) and group 4 received CD8+ T cells 
from mice vaccinated with S91M3αGal(T4). As a control, aged matched untreated, tumor 
free animals were included. Four weeks after tumor inoculation mice were euthanized 
and lungs were collected. Lungs weight was determined and plotted. Results express the 
mean lungs weight. Error bars = SEM. One-way ANOVA p= 0.0004 for all data sets. 
One-way ANOVA excluding tumor free animals p=0.0045. B. Lung pictures of recipient 
mice in each group (excluding tumor free animals). C. T cells from naïve and from mice 
vaccinated with S91MaαGal were cultured in presence of autologous APC pulsed with 
OVA or mTRP-2 peptides. After 6 hours of incubation in presence of brefelidin A cells 
were harvested and the intracellular cytokine TNF-α was detected.  
 
 
 116
Figure 4: Testing for immunodominance of the response induced by 
allogeneic vaccines expressing αGal epitopes  
Mice were immunized i.p. with RRBC to increase the anti-αGalAb titers. One week after 
last RRBC, pulmonary metastases were established by i.v. injection of 5 x 104 viable 
B16F0 cells. Mice received a total of 1x106 vaccine cells as indicated in Materials and 
Methods on days 4, 11 and 18 after tumor inoculation. On day 29, mice were humanely 
euthanized and lungs were collected. Pulmonary tumors were enumerated in a blinded 
manner. One way ANOVA  p<0.0001.  
 
Figure 5. Kinetics of anti-αGalAb after RRBC immunizations in presence or 
absence of αGal(+) allogeneic vaccines 
A. Schematic representation of immunizations and blood collections. Mice were 
immunized with RRBC three times two weeks apart. They received three doses of 1x108 
RRBC administered intraperitoneally. Mice receiving LLC cells were vaccinated at 
weekly intervals starting 7 days after the last RRBC immunization. All mice were bled at 
days 4, 19 and 46 after the last RRBC immunization. 
B. Levels of anti-αGalIgG Ab determined by ELISA. Statistical comparison indicates that 
the anti-αGalIgG Ab titers from the groups of mice receiving RRBC or RRBC plus LLC 
cells are not different at day 4 (t test p= 0.35). However, on days 19 and 46 both groups 
differed significantly indicating that the subcutaneous administration of LLC vaccines 
significantly increased the titers of anti-αGalAb IgG (p= 0.02 for day 19 and p= 0.004 for 
day 46). C. Levels of anti-αGalIgM Ab determined by ELISA. For anti-αGalIgM Ab 
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titers there is no difference among the groups receiving RRBC only and mice receiving 
the LLC test vaccine at any time point (p>0.05 for days 4, 18 and 46). In all experiments 
the level of anti αGalAb (IgG and IgM) of immunized mice differs significantly from 
naive mice (p< 0.01).  
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Supplementary 1 Figure 2 
 
 
Supplementary 2 Figure 1. Growth patterns of mice receiving allogeneic 
cancer vaccines expressing αGal epitopes. 
A. Allogeneic lung cancer vaccine model. Naive mice (males n=14, females n=15),), 
mice injected with RRBC only (males n=10, females n=11) or injected with RRBC and 
vaccinated with 6 doses of LLC vaccine (males n=15, females n=14 n) were weighed for 
6 months after initiation of the study. Statistical comparisons of the growth patterns 
indicate no significant difference among groups. The preferred model to compare the 
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growth patterns was the sigmoidal dose-response (variable slope). All data sets shared the 
same slope (males p=0.1654, females p=0.1822). B. Allogeneic breast cancer model. 
Naive mice (n=9), mice injected with RRBC twice two weeks apart (control, n=13) and 
mice receiving RRBC and EMT-6 vaccine (test group, n=13) were monitored for six 
months after initiation of the study. In the study conducted for allogeneic breast cancer 
model one female from the test group suffered serious trauma around the nose possible 
due to an aggressive dominant female housed in the same cage. This animal showed 
significant weight lost. A different environment and enrichment was provided to this 
animal, which recovered 100% of its initial body weight. This case was annotated as 
severe and transient weight loss not related to the administration of allogeneic breast 
cancer vaccine.  C. Allogeneic melanoma model. Naïve mice (n=12), mice injected twice 
with RRBC three weeks apart (Control, n=9) and test group (B16αGal vaccine, n=17) 
receiving RRBC and six SC doses of B16αGal vaccines (1 million cells /mice/dose were 
monitored for six months after initiation of the study. For all data sets, the preferred 
model to fit the data was the sigmoidal dose-response (variable slope). All data sets 
shared the same slope (p= 0.0706).  
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Supplementary 3 Table 1. Hematology Results in the allogeneic vaccine for 
Lung Cancer Model. Data at 24 hours post LLC vaccines 
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Supplementary 3 Table 2. Hematology Results Allogeneic vaccine for Lung 
Cancer Model. Data 2 months post LLC vaccines 
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Supplementary 3 Table 3. Hematology Results Allogeneic vaccine for Lung 
Cancer Model. Data 6 months post LLC vaccines 
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Supplementary 3 Table 4. Hematology Results Allogeneic vaccine for Breast 
Cancer Model. Data at one week post EMT-6 vaccines 
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Supplementary 3 Table 5. Hematology Results Allogeneic vaccine for Breast 
Cancer Model. Data 6 months post EMT-6 vaccines 
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Supplementary 3 Table 6. Hematology Results Allogeneic vaccine for 
Melanoma Model. Data 2 weeks post B16αGal vaccines 
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Supplementary 3 Table 7. Hematology Results Allogeneic vaccine for 
Melanoma Model. Data 6 months after B16αGal vaccines 
 
Supplementary 4 Table 1. Histopatology Results. Incidence of microscopic 
lesions in the Allogeneic vaccine for Lung Cancer Model 
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Supplementary 4 Table 2. Histopatology Results. Incidence of microscopic 
lesions in the Allogeneic vaccine for Lung Cancer Model 
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Supplementary 4 Table 3. Histopatology Results. Incidence of microscopic 
lesions in the Allogeneic vaccine for Breast Cancer Model 
 
Supplementary 4 Table 4. Histopatology Results. Incidence of microscopic 
lesions in the Allogeneic vaccine for Breast Cancer Model 
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Supplementary 4 Table 5. Histopathology Results. Incidence of microscopic 
lesions in the Allogeneic vaccine for Melanoma model 
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Supplementary 4 Table 6. Histopatology Results. Incidence of microscopic 
lesions in the Allogeneic vaccine for Melanoma model 
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